Category: ACN Newswire

Healthy pipeline, diversification and cost discipline position the Company for long-term growthKey Financial Performance Highlights for the Financial Year (FY2025):- Group’s total revenue for the financial year is RM222.7 million, mainly driven by the e-mobility and energy storage segment, supplemented by the electronics segment.- Recorded LAT of RM40.9 million for Q4FY2025 and LAT of RM27.2 million for the financial year.BANGI, Malaysia, Aug 28, 2025 - (ACN Newswire via SeaPRwire.com) - Technology leader in providing turnkey, intelligent manufacturing automation solutions, Genetec Technology Berhad (“Genetec” or the “Company”), today announced its financial results for the year ended 30 June 2025 (“FY2025”). The Company reported a gross profit of RM12.7 million for FY2025, supported by continued deliveries in the e-mobility and energy storage segments. The Company recorded a loss after tax (LAT), mainly reflecting higher logistics costs and non-operational, one-off expenses, while underlying fundamentals remain intact.Performance was affected by logistics constrains and one-off costs. Despite this, the Company continued to invest in strengthening its capabilities and supporting future project scopes. Profitability is expected to normalise in FY2026 as markets stabilise and as projects are executed effectively. Genetec is also reinforcing its organisation by bringing in experienced professionals into strategic roles, aimed at broadening capabilities and supporting its long-term diversification strategy.Healthy Orderbook through Diversified MarketsThe Company’s order and tender books remain intact and healthy, underpinned by recurring orders from existing clients as well as new opportunities from a more diversified client base across multiple industries and regions.Deepening Engagement with Existing ClientsAlongside diversification, Genetec continues to strengthen partnerships with its existing clients. Recurring orders and new programme awards reflect the trust and confidence these clients place in Genetec’s execution capabilities and proven track record.Global Manufacturing Trends Creating TailwindsGlobal geopolitical shifts are leading manufacturers across industries to re-evaluate their production footprints and enhance operational resilience. This trend is fuelling greater demand for automation solutions that are flexible, cost-competitive, and consistently high in quality. With its Malaysia-based production model, strong international track record, deep technical know-how, and agile manufacturing capabilities, Genetec is well-positioned to support clients as they navigate and adapt to these evolving requirements.Positive Outlook for BESS PipelinesThe Battery Energy Storage System (BESS) segment continues to gain momentum, with Genetec executing projects across domestic and international markets, and seeing growing local interest in BESS solutions for peak shaving following the recent tariff revision.Chief Executive Officer and Co-founder of Genetec, Chin Kem Weng commented, “FY2025 was a year of investment and transition. We made deliberate strategic choices to strengthen our foundation, safeguard delivery timelines, and support new project scopes. While these factors impacted margins in the short term, they reinforce our capabilities and credibility as a trusted partner. We expect profitability to normalise as market stabilise and as we build on execution experience.”“At the same time, our pipelines remain healthy, supported by recurring orders from existing clients and new opportunities across diversified industries and regions. Our inclusion in both the conventional and Shariah FTSE4Good Bursa Malaysia indices reflects the strength of our governance and sustainability practices. As Genetec approaches our 30th year in business, we remain committed to creating long-term value for clients, shareholders, and stakeholders.”About Genetec Technology BerhadGenetec Technology Berhad is a public listed company on the Main Market of Bursa Malaysia Securities Berhad (Stock code: 0104) and a global leader in providing customised, turnkey smart factory automation solutions. With a strong international footprint, it serves a diverse range of industries including electric vehicle (EV), e-mobility and energy storage, automotive, hard disk drives (HDD), consumer electronics, appliances, and pharmaceuticals.For more information please visit: https://genetec.net/.Issued on behalf of Genetec Technology Berhad by Narro CommunicationsFor media enquiries on Genetec Technology Berhad, please contact:Farah Shahrul Narro Communications E: farah@narrocomms.com Joyce ShaminiNarro CommunicationsE: joyce@narrocomms.com Copyright 2025 ACN Newswire via SeaPRwire.com.

SHANGHAI, Aug 28, 2025 - (ACN Newswire via SeaPRwire.com) - Hua Medicine (the “Company”, HKEx: 2552) announced the unaudited consolidated results of the Company and its subsidiaries for the six months ended June 30, 2025 (the “Reporting Period”), as well as the Company's business progress during the first half of the year and future outlook. During the Reporting Period, the commercialization of the Company's core product, HuaTangNing (dorzagliatin tablets), accelerated. The Company’s independent operational capabilities improved significantly. R&D progress advanced smoothly and the Company’s financial performance achieved breakthrough growth, laying a solid foundation for long-term sustainable development.Sales of HuaTangNing increased by 108% year-on-year, with net sales increasing by 112% year-on-year. Reimbursement coverage continued to expand, with a significant increase in prescription volumes across Tier 2 and Tier 3 hospitals, as our comprehensive commercialization strategy achieved significant results.Following the termination of the exclusive promotion service agreement with Bayer, the Company recognized a one-time release of previously deferred income of RMB 1,243.5 million, achieving a profit of RMB 1,183.9 million for the first half of the year. This is the Company's first profit during the performance period.A real-world study (BLOOM) involving 80 centers and 2,000 patients with Type 2 diabetes conducted in China further demonstrated the broad applicability and safety of dorzagliatin.A registration application has been submitted in Hong Kong for Dorzagliatin 75mg (brand name: MYHOMSIS®), aiming to extend its presence across Greater China and Southeast Asia.Gross profit margin improved significantly, as production scale and operational efficiency continued to be optimized.“The first half of 2025 was a critical stage in Hua Medicine’s transformation and development. Following the full takeover of the commercialization of HuaTangNing, the Company achieved double-digit growth in sales and revenue through its independently established sales team, thereby validating the effectiveness of the new business model. We have also submitted a new drug application in Hong Kong, China, laying the foundation for dorzagliatin to expand from China to Southeast Asia and the global market,” said Dr. Li Chen, founder and CEO of Hua Medicin “Dorzagliatin has continued to demonstrate broad therapeutic potential in real-world studies, and new evidence has been found in basic research regarding diabetes remission, cognitive improvement, lipid improvement, and muscle gain, further consolidating Hua Medicine’s global leadership in GKA research and development and treatment. In the future, Hua Medicine will continue to focus on diabetes and the entire field of metabolic diseases, driving innovation through research and development and market expansion to bring the benefits of China's original innovative drugs to more patients worldwide.” Business Highlights and Operational ProgressCommercialization transformation achieved remarkable results, with doubling of sales and profits.Effective from January 1, 2025, the Company terminated its exclusive promotion service agreement with Bayer and fully took over the commercialization of HuaTangNing (å''å ‚å®'®) in China. During the Reporting Period, with unit prices remaining consistent with the same period in 2024, sales of HuaTangNing reached 1,764,000 packs, a year-on-year increase of 108%. Net sales reached RMB217.4 million, a year-on-year increase of 112%. Leveraging strong commercial execution and continuously improving operational efficiency, the Company is moving toward profitability. Hua Medicine has successfully transitioned to a fully independent commercialization phase, confirming growing market demand and the efficient execution capabilities of its independent sales team.Sales of HuaTangNing continued to benefit from its inclusion in China’s National Reimbursement Drug List (NRDL), which took effect in January 2024. Reimbursement coverage under the NRDL has significantly increased accessibility, especially in Tier 2 and Tier 3 hospitals, and played a critical role in accelerating patient adoption.Due to expanded production scale and improved cost efficiency, the Company's gross profit margin increased to 54.2%, higher than 46.5% in the same period last year.With sales revenue growing 112% year-on-year, the Company's sales expenses during the Reporting Period were RMB64.2 million for the six months ended June 30, 2025, growing only 5% compared to the same period last year. The composition of our selling expenses for the six months ended June 30, 2025 changed significantly from the same period in 2024 due to the Company incurring selling expenses directly as a result of assuming sole commercialization responsibilities for HuaTangNing in China, while no longer owing promotion expenses to the former commercialization partner. These figures also reflect a significant positive trend towards profitability and demonstrate our business strategy of optimizing profitability by controlling commercialization sales expenses of HuaTangNing and maximizing production efficiency, where our selling expenses in the first half of 2025 represent approximately 29.5% of total revenue whereas in the first half of 2024, our selling expenses represented approximately 59.5% of total revenue. After terminating the exclusive promotion service agreement with Bayer, the Company recognized a one-time release of previously deferred income of RMB1,243.5 million and transitioned to self-driven growth. Hua Medicine achieved a pre-tax profit of RMB 1,183.9 million for the first half of the year, marking a key milestone of Hua Medicine towards sustainable profitability.As of June 30, 2025, the cash balance was RMB1,022.8 million, laying a solid foundation for the Company's future R&D and commercialization initiatives.Clinical research continues to deepen, with new evidence supporting treatment potentialHua Medicine is conducting multiple post-marketing studies to evaluate the long-term safety and effectiveness of dorzagliatin across diverse patient populations, both in monotherapy as well as in combination with other popular approved anti-diabetic drugs, such as GLP-1 receptor agonists, insulin, DPP-IV inhibitors and SGLT-2 inhibitors. These studies are generating new clinical insights into glucose control, cognitive outcomes, and potential for diabetes remission.A real-world study (BLOOM) is being conducted in 2,000 patients with Type 2 diabetes across 80 centers in China. BLOOM has already completed one-year follow-up in over 1,000 participants. In the real-world setting, BLOOM further demonstrates the broad applicability and safety of dorzagliatin. Patients receiving dorzagliatin in routine clinical practice present with a heterogeneous mix of comorbidities, including various cardiovascular and renal disorders and are managed with multiple concomitant medications. In addition to metformin, more than 60% of patients concurrently used SGLT-2 inhibitors, insulin, GLP-1 receptor agonists, or DPP-IV inhibitors and other anti-diabetic drugs with dorzagliatin. In monotherapy or in combination with the popular above-mentioned anti-diabetic drugs, dorzagliatin was generally well tolerated, and its safety profile remained consistent with previously established data.Hua Medicine presented new data at the 2025 American Diabetes Association (ADA) conference, reinforcing dorzagliatin’s potential as a disease-modifying therapy. Insights into the novel mechanism of action (MOA) of dorzagliatin as a therapeutic GKA were published in Diabetes.Research and Development Pipeline and Future OutlookThe company filed its application for registration of dorzagliatin 75mg in Hong Kong as MYHOMSIS®, aiming to extend its presence across Greater China and southeast Asia.We are continuing expansion on our product pipeline through development of fixed dose combination of metformin and dorzagliatin for patients who have failed to control blood glucose levels while using high dose metformin (daily dose>1500 mg). In the loose dose combination study-DAWN Trial, dorzagliatin add-on to metformin provided HbA1c reduction of greater than 1% and post meal glucose reduction of greater than 5 mmol/L. These desirable glycemic control levels coupled with a very safe 0.8% hypoglycemic rate would suggest strong potential demand for a branded oral anti-diabetic medication using a convenient fixed dose combination of dorzagliatin and metformin. The Pre-IND submission has been achieved in August 2025, and we are expected to initiate the bioequivalence study in early 2026.We are also advancing the combination of dorzagliatin with GLP-1RA, SGLT-2 inhibitors, insulin and DPP-IV inhibitors through combined effects in collecting real world evidence and proof of concept studies in animal models. The synergy between dorzagliatin with these agents has the potential to expand our indications into other diseases in metabolic disorders, such as obesity and MASH.We continue to enhance our collaborations with leading international research institutions. A Phase I investigator-initiated trial supported by the Group and conducted at the University of Pennsylvania – designed to evaluate the efficacy and safety of dorzagliatin in patients with cystic fibrosis-related diabetes (CFRD) – has received clearance from the U.S. FDA.We will continue our engagement in diabetes prevention, opportunities in metabolic disorder related neurodegeneration disease and eventually find a new way to increase healthy life span and longevity in humans.We continue to invest in digital technology platforms to create synergies across functions and enhance branding opportunities using AI technology.As illustrated in our product pipeline chart, we will continue to advance our R&D efforts for both dorzagliatin and our 2nd generation GKA on our own as well as in collaboration with academic and strategic partners. We are working on the registration of dorzagliatin in Hong Kong and continue to seek partnerships in Southeast Asia and Belt and Road nations. In addition, we will continue our business development efforts on our 2nd generation GKA for the global markets based on the initial success of the Phase 1 single-ascending dose study in the United States and the initiation of our Phase 1 multiple ascending dose study planned for late 2025 or early 2026.Financial SummaryAs of June 30, 2025- Bank balances and cash amounted to approximately RMB 1,022.8 million.- Total revenue was approximately RMB217.4 million, representing a year-on-year increase of 112%. Sales of HuaTangNing (å''å ‚å®'®) reached 1,764,000 packs, representing a year-on-year increase of 108%.- Total gross profit was approximately RMB117.8 million, representing a year-on-year increase of 147%. Gross margin was approximately 54.2%, increased by approximately 7.7 percentage points, as compared with the six months ended June 30, 2024.- Total other income amounted to approximately RMB1,254.6 million , of which Bayer's one-time release of previously deferred income was RMB1,243,5 million.- Total expenditures were approximately RMB187.1 million, of which research and development expenditure was approximately RMB65.8 million.- Profit before tax was approximately RMB1,183.9 million, representing approximately 932% for the six months ended June 30, 2025Forward-Looking StatementsThis document contains statements regarding Hua Medicine’s future expectations, plans, and prospects for the Company and its products. These forward-looking statements pertain only to events or information as of the date they are made and may change due to future developments. Unless required by law, we are not obligated to update or publicly revise any forward-looking statements or unexpected events after the date of such statements, regardless of new information, future events, or other circumstances. Please read this document carefully and understand that our actual future performance or results may differ materially from expectations due to various risks, uncertainties, or other legal requirements.About Hua MedicineHua Medicine (The “Company”) is an innovative drug development and commercialization company based in Shanghai, China, with companies in the United States and Hong Kong. Hua Medicine focuses on developing novel therapies for patients with unmet medical needs worldwide. Based on global resources, Hua Medicine teams up with global high-calibre people to develop breakthrough technologies and products, which contribute to innovation in diabetes care. Hua Medicine's cornerstone product HuaTangNing (dorzagliatin tablets), targets the glucose sensor glucokinase, restores glucose sensitivity in T2D patients, and stabilizes imbalances in blood glucose levels in patients. HuaTangNing was approved by the National Medical Products Administration (NMPA) of China on September 30th, 2022. It can be used alone or in combination with metformin for adult T2D patients. For patients with chronic kidney disease (CKD), no dose adjustment is required. It is an oral hypoglycemic drug that can be used for patients with Type 2 diabetes with renal function impairment.For more informationHua MedicineWebsite: www.huamedicine.comInvestors E-mail: ir@huamedicine.comMedia E-mail: pr@huamedicine.comPress DisclaimerFor accuracy and completeness in context, information related to products marketed in China in this material, especially those identified or required, should comply with documents approved by Chinese regulatory authorities.Additionally, such information should not be interpreted as a recommendation or promotion of any drug or treatment, nor should it replace medical advice from healthcare professionals. For medical-related matters, please consult a healthcare professional. Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 28, 2025 - (ACN Newswire via SeaPRwire.com) - Shoucheng Holdings Limited (0697.HK, hereinafter referred to as “Shoucheng Holdings”), Beijing Shoucheng Robotics Technology Industry Co., Ltd. (hereinafter referred to as “Shoucheng Robotics”), IAT Automobile Technology Co., Ltd. (300825.SZ, hereinafter referred to as “IAT”), and Beijing IATROBOT Technology Co., Ltd. (hereinafter referred to as “IATROBOT”) officially signed a strategic cooperation framework agreement.The four parties will leverage their respective strengths to carry out comprehensive cooperation in technological innovation, application deployment, industry chain collaboration, and talent cultivation within the robotics sector, jointly accelerating the development of new business models in the “Robotics + Automobiles” field.I. Industry Background: Robotics Entering the Acceleration Phase of Application DeploymentAt present, the global robotics industry is in a stage of rapid development, with national strategies and policies being introduced intensively. On August 26, the State Council officially released the Opinions of the State Council on Deeply Implementing the “AI+” Initiative (Guo Fa [2025] No. 11), which explicitly calls for promoting the extensive and in-depth integration of artificial intelligence with various industries and fields across the economy and society, and accelerating the formation of new models of intelligent economy and intelligent society characterized by human-machine collaboration, cross-industry integration, and co-creation.Under this national strategy, the robotics industry is shifting from “technological breakthroughs” to “application deployment.” Automobiles and robotics, as two highly complementary industries, are increasingly showing a trend of cross-sector integration. The cooperation between Shoucheng Holdings and IAT Group, under the dual drivers of favorable policy and strong market demand, will inject new momentum into robotics applications across key segments such as R&D, manufacturing, transportation, and mobility services.IAT is a leading enterprise in China’s automotive design field and the only independent automotive design company listed on the A-share market. The company provides full-process services ranging from complete vehicle R&D and design to core component manufacturing, while pursuing a globalization strategy of “technology + supply chain.” According to public information, IAT has served more than 80 clients and participated in the development of nearly 500 vehicle models. Its clients include major OEMs such as FAW, Dongfeng, BAIC, Geely, emerging EV brands, as well as joint-venture automakers. This highlights IAT’s strong OEM resources and delivery capabilities across the automotive value chain.At the same time, through its subsidiary — Beijing IATROBOT Technology Co., Ltd. — IAT has officially entered the robotics sector. IATROBOT is dedicated to building an integrated R&D, design, and simulation training platform, capable of supporting multi-scenario robotics development from simulation and testing to optimization. The company has already launched multiple R&D projects, including wheeled robots, underwater robots, drilling robots, and pet-care robots, demonstrating its potential in cross-scenario development and industry collaboration. The involvement of IATROBOT expands the scope of this cooperation beyond traditional automotive design, providing important support for the integration of robotics R&D, simulation, and automotive industrialization.By partnering with IAT and IATROBOT, Shoucheng will be able to embed robotics technologies deeply into the core stages of the automotive value chain, such as vehicle manufacturing, intelligent assembly, and production line testing. This will enable robots to truly enter the production line and accelerate industrial adoption. This strategic cooperation is not merely a technological connection — it leverages IAT’s extensive OEM client network to move robotics scenarios from “next-door demonstrations” directly into the “factory workshop,” bridging the crucial pathway between R&D validation and scaled industrial delivery.II. Key Areas of Cooperation: Balancing R&D Breakthroughs and Application DeploymentGuided by the State Council’s “AI+” Initiative, the four parties will anchor their collaboration on the full chain of “technology R&D — industrial application — ecosystem co-construction,” working together to drive industrial innovation. The cooperation will focus on the following areas to promote the deep integration of robotics and automobiles:(1) Technological Innovation and Joint R&DThe four parties will jointly build an integrated robotics R&D and simulation platform, drawing on the comprehensive R&D system of the automotive industry. The focus will be on achieving breakthroughs in key areas such as motion control, structural optimization, automotive-grade components, and large-scale manufacturing. Leveraging NVIDIA Isaac/Omniverse technology, the parties will co-develop an integrated simulation training platform that not only supports simulation of robotics applications in automotive R&D, manufacturing, and testing, but also enables cross-scenario simulations such as collaborative operations between autonomous driving vehicles and logistics robots.In addition, a mechanism for data and outcome sharing will be established: Shoucheng Holdings will provide operational data resources from transportation and mobility scenarios, while IAT will contribute expertise in automotive engineering and robotics R&D, together forming a complete closed loop spanning simulation — R&D — validation — production line application.(2) Priority Procurement and Synergy MechanismAcross R&D design, simulation training, complete machine and component supply, the four parties will adopt a priority procurement mechanism, under which signatories will be given preference as partners under equivalent conditions. Shoucheng Holdings and Shoucheng Robotics will focus on product promotion, distribution, and supporting services, while IAT and IATROBOT will concentrate on technology R&D, engineering validation, and customized whole-machine development.The parties will also work together to advance secondary development of robotic systems, ensuring optimal adaptation of robotics products to scenarios such as automotive production lines, intelligent assembly, and line testing. Through division of labor and collaborative mechanisms, a complementary cycle of product supply — technological innovation — application feedback will be established, accelerating the conversion of results and enhancing commercialization efficiency.(3) Talent DevelopmentLeveraging the research and industrial platforms of Shoucheng, IAT, and their partners, the four parties will jointly carry out technological problem-solving, simulation training, and application pilots, providing researchers and engineers with cross-industry, cross-scenario practical environments. Regular technical seminars and industry forums will be held, inviting experts and upstream and downstream enterprises to participate, thereby establishing a joint talent development mechanism. This initiative aims to cultivate a new generation of young researchers with both automotive engineering backgrounds and practical experience in robotics industrialization, laying a solid talent foundation for long-term growth.(4) Expanding Development HorizonsThe four parties will closely align with national strategies for “AI+” and robotics industry development, with a focus on scaling up “Robotics + Automobiles” applications in R&D, manufacturing, testing, and mobility services. Building on this foundation, the cooperation will gradually extend into broader fields such as smart transportation, intelligent manufacturing, healthcare, education, and public services, covering the design, R&D, production, testing, and commercialization of robots and core components. At the same time, by integrating capital and industry, the parties will drive coordinated upgrades across the value chain, ultimately forming a full-cycle closed loop from R&D validation to large-scale application. This will create a demonstrative “Robotics + Automobiles” application matrix, achieving mutual benefits and long-term value creation.III. Strategic Significance: Establishing a New Benchmark for Robotics ApplicationsThe greatest value of the robotics industry lies in real-world applications, and “Robotics + Automobiles” stands out as one of the most promising and high-potential application directions. From complete vehicle R&D to intelligent manufacturing, from traffic scheduling to smart mobility, robots will create tremendous value across the entire automotive value chain.Shoucheng Holdings, leveraging its capital platform, ecosystem resources, and industrial fund advantages, has invested in leading domestic enterprises such as Unitree Robotics, Galbot, Noetix Robotics, Galaxea-AI, and Booster Robotics, equipping it with the capability to integrate frontier technologies. Shoucheng Robotics has established collaborations with hundreds of high-quality upstream and downstream enterprises, making it one of the most comprehensive resource-linking platforms in China. IAT and IATROBOT, in turn, bring mature automotive engineering systems into robotics R&D and industrialization. Together, the combined strengths of both sides will form a complete pathway of “R&D — iteration — application — scale-up.”By joining forces with IAT, Shoucheng will further integrate its scenario resources and industrial ecosystem with IAT’s expertise in vehicle R&D, engineering capabilities, and industrialization experience. Over the next one to two years, the cooperation will focus on the deep integration of “Robotics + Automobiles,” taking the lead in demonstrating large-scale applications across vehicle R&D, production and manufacturing, smart transportation, and mobility services. This will accelerate the transition of robotics from laboratories to industrialization and large-scale deployment, creating a demonstrative “Robotics + Automobiles” application matrix. At the same time, the cooperation will also look to the international market, bringing Chinese solutions to the global stage, fostering new quality productivity, and generating long-term value for shareholders.Posted by All Way Success Company Limited for Shoucheng Holdings www.shouchengholdings.com [HKSE:0697, FRA:SHVA, OTCPK:SHNHF] Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 29, 2025 - (ACN Newswire via SeaPRwire.com) - China Everbright Limited ("CEL" or "the Company", stock code: 165.HK) announced its Interim results for the six months ended 30 June 2025 ("the reporting period").Highlights of the 2025 Interim Results- Strong Growth: Total income reached HK$2,068 million, representing a significant increase compared with the same period last year;- Turning Around from Loss to Profit: During the reporting period, the Company recorded a profit of HK$650 million, of which the net profit attributable to shareholders of the Company was HK$399 million, successfully turning around from a net loss;- Fundraising Increase: The total assets under management (AUM) of CEL's funds amounted to approximately HK$119.4 billion, with new fundraising amounting to approximately HK$2,741 million;- Successful Exits: The total exits from funds and principal investments amounted to HK$2.018 billionï¼›with a MOIC (multiple on invested capital) of approximately 2.78 times;- Cost Control and Efficiency Enhancement: Enhanced lean management led to a 10% year-on-year decrease in operating costs and a 38% year-on-year reduction in finance costs;- Adequate Liquidity: The Company had cash and cash equivalents of approximately HK$8.1 billion;- Steady Dividend: An interim dividend of HK$0.05 per share for 2025.In the first half of 2025, China's private equity industry entered a more stable stage of development. Leveraging its strengths as patient capital, CEL maintained strategic focus, seized market opportunities with precision, and promptly adjusted its fundraising, investment, management, and exit strategies. By consolidating its core businesses, gradually unlocking value potential, and significantly improving overall operational efficiency, the Company achieved a strong rebound in performance.During the reporting period, CEL realised total income of HK$2,068 million, representing a significant increase of HK$2,182 million from the same period last year. This was mainly due to a significant increase in investment income, which fully demonstrated the Company's sound investment vision and solid foundation in long-term investing. The Company recorded a profit of HK$650 million, of which the net profit attributable to shareholders of the Company amounted to HK$399 million, successfully turning around from a net loss attributable to shareholders of HK$1,282 million in the same period last year, representing a significant improvement in performance.Meanwhile, the Company continued to strengthen its refined management, sustaining healthy and steady business development. During the reporting period, operating costs represented a year-on-year decrease of 10%, with proactive leverage reduction measures implemented. The gearing ratio decreased by 2% compared with the end of 2024, while finance costs fell 38% year-on-year, demonstrating significant results in cost control and efficiency improvement. As at the end of June 2025, the Company had cash and cash equivalents of approximately HK$8.1 billion, representing sufficient liquidity.By concentrating its resources and business focus on high-potential products, the Company further reinforced its core business. During the reporting period, with new fundraising amounting to approximately HK$2,741 million, the total AUM of CEL’s funds amounted to approximately HK$119.4 billion, managing 72 fund products and covering primary market funds, secondary market funds, and fund of funds. During the reporting period, the Company invested in a total of 9 projects and exited, fully or partially, from 46 project.Following the practice of sharing the Company's operating results with shareholders, the Board declared interim dividend of HK$0.05 per share for 2025 (2024 interim dividend: HK$0.05 per share).Business Highlights in the First Half of 2025Firstly, CEL Harnessed the Strengths of Group-Based Operations to Enhance Fundraising SynergyIn the first half of 2025, the Company successfully launched the Huaian Hongze Guangqi Fund and the Xiamen Marine High-Tech Industrial Development Fund, with a total scale of RMB2.5 billion. The Huaian Fund targets growth-stage projects in the areas of new energy, new materials, and intelligent manufacturing, with its first round of capital contribution completed in the first half of the year. The Xiamen Marine Fund is dedicated to incubating and transforming scientific and technological innovations in the marine sector, driving the high-quality development of the marine economy. At the same time, several other funds have been approved and are progressing smoothly, following the established plan.Secondly, CEL Strengthened Core Businesses to Drive Robust Recovery in PerformanceDuring the reporting period, the Company total exits from funds and principal investments amounted to HK$2.018 billion. This include the full exit from Xpeng Motors, DAPU Telecom, and Taboola, alongside partial exit from iSoftStone, Dekon Food and Agriculture, 4Paradigm, and other projects. With a MOIC (multiple on invested capital) of approximately 2.78 times, these exits significantly boosted the DPI of multiple funds, generating substantial returns for LPs. Several listed projects, including Circle, Dekon Food and Agriculture, and NetEase Cloud Music, delivered strong market performance in the first half of the year, making notable contribution to the Company's investment returns. In the first half of the year, secondary market funds expertly capitalised on structural opportunities, achieving impressive investment performance. Notably, the Everbright Convertible Bond Opportunity Fund ranked second among similar funds in Barclays' performance rankings.Thirdly, CEL Anchored Strategy Around Scientific and Technological Innovation, With a Particular Focus on Key Industry SectorsGuided by deep industrial insight and a forward-looking strategic vision, the Company accelerated its investment activity in the first half of the year. It targeted emerging strategic industries such as artificial intelligence, chips and semiconductors, and biomedicine, with a total investment of approximately HK$264 million by funds. We have nurtured and supported a number of technology leaders, including Yangtze Memory and Wuhan Xinxin (both prominent domestic memory chip producers), HengYi Biotech (a company engaged in the research and development of innovative drug for tumors and autoimmune diseases), J-Sensor (astrategic supplier of domestic industrial automation modules and core sensors for new energy vehicles), and Tec-Do (a service provider in the field of big data and BI), among others. These investments reflect our commitment to strengthening China’s science and technology enterprises. Meanwhile, CEL supported excellent sub-funds such as Jinyi Capital and Eastern Bell Capital through its FoF platforms. These FoF investments allow us to fully leverage the advantages of resource amplification, risk diversification, and diversified returns.Fourthly, CEL Optimise Business Management to Unlock Growth MomentumIn the first half of the year, the Company continued to optimise its financing structure and took full advantage of the domestic interest rate cut cycle, issuing RMB3 billion in the first tranche of its 2025 medium-term notes at a coupon rate of 2.09% per annum — the lowest coupon rate in the Company's bond issuance history. During the reporting period, the Company's overall financing cost declined by 133 basis points year-on-year to 3.14%, while its finance costs reduced by 38% year-on-year. Operating costs also recorded year-on-year decrease of 10%, underscoring the solid progress made in reducing costs and increasing efficiency. The Company continued to optimise its risk management framework. CEL advanced the classification of risk assets, reinforced dynamic valuation management, and established a risk monitoring and early warning system, thereby improving the effectiveness of risk prevention and control across the full business cycle.Fifthly, CLE Enhanced Public Services and Upgraded Commercial Consumption.CEL leveraged its industrial strengths to enhance the quality of its products and services, catering to the growing demand for consumer services among citizens. In the commercial consumption arena, EBA successfully launched 18 "IMIX Park" shopping centres across nine cities nationwide,managing approximately 2.6 million square metres in total. These centres created approximately 37,700 jobs, attracted approximately 121 million customer visits, and hosted more than 4,500 tenant merchants in the first half of 2025. During the reporting period, Phase I of the "Zhongguancun ART PARK IMIX Parks", a flagship consumption infrastructure and urban renewal project in Beijing, opened smoothly, significantly upgrading the consumer experience and giving a strong boost to domestic demand.Sixthly, Key Portfolio Companies Maintain Stable Growth with Strong ResilienceThe core business of China Aircraft Leasing Group Holdings Limited (CALC) progressed steadily with remarkable improvements in operating quality and efficiency. The net profit attributable to shareholders recorded a year-on-year increase. As of June 30, 2025, CALC’s fleet reached 181 aircraft, leased to 41 airlines across 22 countries and regions. Everbright Senior Healthcare has been seizing the development opportunities in China's healthcare industry. As of 30 June 2025, Everbright Senior Healthcare has 237 institutions of various types in 49 cities across the country, it managed more than 30,000 beds, with occupancy rates increasing by 1.77%. Meanwhile, Terminus continued to deepen the integration of AI technology across multiple industries, driving intelligent transformation and implementing localised AI applications and digital-intelligent solutions, while receiving multiple authoritative certifications.Seventhly, CEL Strengthened ESG Framework to Promote Sustainable DevelopmentDuring the reporting period, CEL continued to promote the construction of its ESG system. the Company maintained an "A" rating in the MSCI ESG Rating and received the "BEST ESG (S)" award from the Hong Kong Investor Relations Association (HKIRA). The Company earnestly fulfilled its role as a corporate citizen by leveraging its own capabilities, organizing and participating in 46 cultural and social welfare activities in the first half of the year, serving over ten thousand people, and upholding high standards in discharging its social responsibilities.In the first half of 2025, under the strong leadership of the Everbright Group, the guidance of the Board of Directors, and the collective efforts of all employees, the Company achieved significant improvements in operational efficiency and quality, with new drivers of growth continuing to strengthen, resulting in hard-won achievements. As China's economy continues to improve and policy support intensifies, the Chinese private equity industry will embark on a new journey of high-quality development. CEL will seize market opportunities, capitalise on the momentum, and lay a solid foundation for a strong start to the 15th Five-Year Plan. In the second half of the year, CEL will continue to adhere to the overall principle of seeking progress while maintaining stability, continue to focus on revenue growth and cost control, optimise operational management, seize opportunities in key business areas such as fundraising, investment, management, and exit, leverage the cross-border platform and the synergistic advantages of the group, cultivate long-term patient capital, and advance the "five major financial initiatives", through scientific strategic planning, professional investment teams, and rigorous risk management, and continuously create value for shareholders.China Everbright Limited, https://www.everbright.com/en [SHSE:601818][HKEX:00165][OTCPK:CEVIF][OTCPK:CEVIY] Copyright 2025 ACN Newswire via SeaPRwire.com.

佛羅里達州西棕櫚灘, 2025年8月28日 - (亞太商訊 via SeaPRwire.com) - U.S. Polo Assn.是美國馬球協會（United States Polo Association, USPA）的官方運動品牌，現已達成多年合作協議，成為棕櫚灘馬拉松的新任冠名贊助商。由 Ken Kennerly 的 K2 Sports Ventures 擁有並營運的 U.S. Polo Assn. 棕櫚灘馬拉松，將於 2025 年 12 月 13-14 日在佛羅里達州西棕櫚灘市中心舉行。美國馬球協會馬拉松這項享有盛譽的馬拉松賽事因其美麗的濱水景觀和椰林大道而聞名，吸引來自全美乃至世界各地的跑者，在寒冷的冬季感受佛羅里達的溫暖。該賽事同時也是享有盛名的波士頓馬拉松的資格賽。USPA Global 總裁兼首席執行官 J. Michael Prince 表示：“U.S. Polo Assn. 很榮幸能夠成為棕櫚灘馬拉松的冠名贊助商。這是一項標誌性的賽事，就像我們的品牌一樣，深深植根於充滿活力的棕櫚灘縣社區。儘管我們這一個受運動啟發的品牌已經在全球 190 多個國家擁有廣泛的影響力，但我們的核心與傳承正是在棕櫚灘。這裡是 USPA Global、美國馬球協會以及全球最具聲望的馬球勝地——USPA 國家馬球中心的所在地。”賽事週末活動將於 12 月 13 日（星期六）上午 7:30 舉行 5 公里和 10 公里賽，隨後在 12 月 14 日（星期日）上午 6:00 舉行主賽事，包括馬拉松、半程馬拉松以及馬拉松接力賽。目前已開放早期報名：馬拉松報名費為 130 美元，半程馬拉松為 100 美元；10 公里早期報名費為 60 美元，5 公里為 45 美元。報名請訪問 palmbeachmarathon.com。健康與健身博覽會（Health and Fitness Expo）將與選手領取參賽包同時進行，時間為 12 月 12 日（星期五）中午 12:00 至下午 6:00，以及 12 月 13 日（星期六）上午 10:00 至下午 6:00，地點在西棕櫚灘 Datura 街 104 號的 Meyer Amphitheatre。博覽會將展示最新的健康與健身產品和服務、跑步裝備，以及未來賽事相關資訊。Kennerly 表示：“我們非常高興能迎來像 U.S. Polo Assn. 這樣享譽全球的品牌成為棕櫚灘馬拉松的冠名贊助商。這對賽事的未來以及其對全球跑者的吸引力來說，都是一件極其重要的事情。棕櫚灘是全球公認的一流目的地，我們期待著賽事不僅能在本地社區持續發展，同時也能在國際舞台上不斷壯大。”U.S. Polo Assn. 品牌產品涵蓋男裝、女裝、童裝，以及配飾、行李箱、手錶、鞋履、家居用品等，並透過獨立零售店、百貨商店、U.S. Polo Assn. 品牌專賣店以及電子商務渠道，在全球 190 個國家進行銷售。Prince 補充道：“與棕櫚灘馬拉松的合作，讓我們能夠共同慶祝體育卓越、社區精神、健康與福祉，以及那份將我們在本地與全球相連的運動熱情。從馬球賽場到棕櫚灘的街道，我們從全力以赴的運動員身上汲取靈感，並期待能共享那份激情、友誼以及世界級競賽氛圍，這正是棕櫚灘馬拉松的獨特魅力所在。”本次賽事還將支持即將公布的本地慈善項目。由赫斯特（Hearst）集團旗下的 ABC 聯盟台 WPBF 25 將繼續擔任賽事官方轉播電視台，不僅會在賽前和賽後透過所有電視頻道和數位平台進行廣泛報導，還將在馬拉松比賽當天上午進行現場直播。WPBF 25 總裁兼總經理 Caroline Taplett 表示：“WPBF 25 非常高興能夠連續第二年擔任 U.S. Polo Assn. 棕櫚灘馬拉松的官方轉播電視台，這再次體現了我們致力於將這樣一項獨特而激動人心的賽事帶給社區的承諾。與我們出色的合作夥伴 Ken Kennerly 及馬拉松團隊攜手，我們將全力推動社區聯繫更加緊密，支持本地企業，並激勵來自本地、全國乃至全球的參賽者齊聚美麗的南佛羅里達，共同參與這場獨一無二的體驗。”關於 U.S. Polo Assn. U.S. Polo Assn. 為美國馬球協會（USPA）之官方品牌，該協會創立於 1890 年，是北美最大馬球俱樂部與馬球運動員聯盟。今年，U.S. Polo Assn. 與美國馬球協會（USPA）共同慶祝品牌成立 135 週年，持續從體育汲取靈感。 該品牌在全球範圍內贊助大型馬球賽事，其中包括每年在棕櫚灘 USPA 國家馬球中心（NPC）舉行的 美國馬球公開賽®（U.S. Open Polo Championship®），這是美國最頂級的馬球賽事。U.S. Polo Assn. 擁有數十億美元的全球品牌價值，並透過逾 1,100 間品牌零售店及數千個銷售據點，在全球超過 190 個國家提供男裝、女裝、童裝、配件與鞋類產品。透過與美國 ESPN、歐洲的TNT和印度 Star Sports 的歷史性協議，U.S. Polo Assn. 贊助的多項世界頂級馬球賽事首次轉播至全球數百萬體育迷，讓這項激動人心的運動登上世界舞台。據《License Global》報導，U.S. Polo Assn. 長期被評為全球頂尖體育授權品牌之一，與 NFL、PGA Tour 和 Formula 1 並列。此外，該品牌亦因於全球及數位市場的成長，獲得多項國際獎項肯定。 U.S. Polo Assn. 曾登上《富比士》、《財富》、《現代零售》和《GQ》等主流媒體，也多次出現在 Yahoo Finance 與 Bloomberg 等財經平台。關於 U.S. Polo Assn. 棕櫚灘馬拉松U.S. Polo Assn. 棕櫚灘馬拉松是一項頂級的冬季長跑賽事，每年在西棕櫚灘舉行，設有多種賽程，適合各類跑者參加，包括全程馬拉松、半程馬拉松、10 公里、5 公里以及四人馬拉松接力。賽事路線為 100% 平坦且經 USATF 認證，並具備波士頓馬拉松資格賽資格。賽道風景優美，跑者不僅能體驗充滿活力的西棕櫚灘市中心，還能沿著棕櫚樹成蔭的 Flagler Drive 前行，途經歷史街區，並欣賞到閃耀的濱水景觀。該賽事同時也支持社區和慈善事業。詳情請訪問 palmbeachmarathon.com 。聯絡資訊Stacey KovalskyU.S. Polo Assn. skovalsky@uspagl.com(954) 673-1331Gary FermanSpecialty Sports(954) 558-5203來源: U.S. Polo Assn. Copyright 2025 亞太商訊 via SeaPRwire.com.

香港，2025年8月28日 - (亞太商訊 via SeaPRwire.com) – 商湯集團股份有限公司（「商湯集團」或「公司」，股份代號：0020）今日公佈截至2025年6月30日止半年度（「2025年上半年」）的中期業績。2025年上半年，商湯集團業績超出市場預期，總收入按年增長36%，達人民幣24億元；其中，生成式AI收入連續第三年高速增長，增幅達73%；經調整虧損淨額按年和按月均大幅收窄，按年下降50%；貿易應收回款額32億元，以96%大幅提升，達歷史新高。截至2025年上半年，集團的總現金儲備132億元。2025年上半年，商湯持續深化「1+X」戰略並取得實質性進展，完成業務動能穩健和結構優化。「1+X」以生成式AI與視覺AI作為「1」的核心業務，亦是雙引擎，而「X」代表的X創新業務板塊以孵化創新生態為核心戰略，聚焦智能駕駛、智慧醫療、家用機械人、智慧零售等四個賽道。生成式AI佔集團收入進一步提升至77%，日日新大模型多模態能力躋身世界前沿，大模型應用圍繞「生産力工具」和「互動工具」 兩大場景，快速提升滲透率和客戶忠誠度。當中生産力工具以商湯「小浣熊」産品為代表，提供金融、教育、政務三大版本，用戶數突破300萬。在互動工具領域，「日日新 V6.5」實現了文本與音視頻融合，多模態實時互動時數年內增長510%。視覺AI重啓增長曲綫，以高質量客戶策略和領先市場佔有率，實現利潤空間與現金流雙向改善。截至2025年6月底，視覺AI板塊服務國內外客戶660餘家，複購比例57%，上半年海外商機儲備與新訂單按年顯著增長。組織上，圍繞「1」和「X」進行二次聯合創業，形成專業化與多元化兼備的領導架構，針對創新業務任命獨立的聯創團隊，實現「X創新業務」在戰略重組後釋放經營活力與資本市場吸引力。商湯科技董事長兼首席執行官徐立博士表示：「在國務院發佈《關於深入實施「人工智能+」行動的意見》重要舉措的背景下，商湯緊抓落地機遇，深耕行業領域，以生成式AI與視覺AI為雙引擎，使商湯在繼續保持視覺AI龍頭地位基礎上，抓住生成式AI 所帶來的歷史性窗口，為員工、客戶和股東持續創造價值。」2025年上半年集團核心經營亮點- 整體收入按年增長36%，達到24億元人民幣，增速較往年進一步提升；經調整EBITDA與經調整淨虧損顯著改善，按年收窄幅度分別達72.5%和50%；- 應收款回款金額創歷史新高，達32億元人民幣，按年增長96%；貿易應收周轉天數同比縮短49%；- 經營活動現金流淨流出按年大幅收窄82%，現金創造能力不斷增强；總現金儲備攀升至132億元人民幣，為集團聚焦長期戰略實施提供了充裕的資金保障。關於商湯作為人工智能軟件公司，商湯科技以「堅持原創，讓AI引領人類進步」為使命，旨在持續引領人工智能前沿研究，持續打造更具拓展性更普惠的人工智能軟件平台，推動經濟、社會和人類的發展，並持續吸引及培養頂尖人才，共同塑造未來。商湯科技擁有深厚的學術積累，並長期投入於原創技術研究，不斷增强行業領先的多模態、多任務通用人工智能能力，涵蓋感知智能、决策智能、智能內容生成、自然語言處理等關鍵技術領域，同時包含AI芯片、AI傳感器及AI算力基礎設施在內的關鍵能力。此外，商湯前瞻性打造新型人工智能基礎設施——商湯AI大裝置SenseCore，打通算力、算法和平台，並在此基礎上建立「商湯日日新SenseNova」大模型及研發體系，以低成本解鎖通用人工智能任務的能力，推動高效率、低成本、規模化的AI創新和落地，進而打通商業價值閉環，解决長尾應用問題，引領人工智能進入工業化發展階段。商湯科技業務涵蓋生成式AI、視覺AI和X創新業務，相關産品與解决方案深受客戶與合作夥伴好評。商湯倡導「發展」的人工智能倫理觀，並積極參與有關數據安全、隱私保護、人工智能倫理道德和可持續人工智能的行業、國家及國際標準的制訂，與多個國內及多邊機構就人工智能的可持續及倫理發展開展了密切合作。商湯《AI可持續發展道德準則》被聯合國人工智能戰略資源指南選錄，並於2021年6月發表，是亞洲唯一獲此殊榮的人工智能公司。目前，商湯科技已於香港交易所主板掛牌上市。商湯在香港、上海、北京、深圳、成都、杭州、西安、新加坡、曼谷、吉隆坡、利雅得、阿布扎比、杜拜、首爾等地設立辦公室。另外，商湯科技在德國、泰國、印尼、菲律賓等國家均有業務。更多資訊，請瀏覽商湯科技網站、微信、微博和領英。 Copyright 2025 亞太商訊 via SeaPRwire.com.

財務摘要 (未經審核)（港幣千元）截至六月三十日止六個月2025年2024年收入122,775135,347毛利47,27748,767本公司所有者應佔溢利8,17218,510毛利率39%36%每股基本盈利 (港仙)0.581.31香港，2025年8月28日 - (亞太商訊 via SeaPRwire.com) – 中國優質葡萄酒生產商王朝酒業集團有限公司（「王朝」或「集團」）（股份代號：00828）今日公佈截至2025年6月30日止未經審核之中期業績。2025年上半年，由於集團加強沿海地區乾白酒市場的開拓力度，推出新的白葡萄酒及起泡葡萄酒產品，集團白葡萄酒產品的銷售收入保持良好勢態。但受中國宏觀經濟及消費市場波動的影響，集團產品（尤其是高端葡萄酒產品）銷量下跌，以及由於推廣及宣傳開支增加，集團2025年上半年收入較2024年同期下跌9%至約1.23億港元，本公司所有者應佔溢利較2024年同期減少56%至約8.2百萬港元，每股基本盈利約為每股0.58 港仙。期內由於產品組合優化，集團毛利率由去年同期的36%上升至39%。集團白葡萄酒產品的銷售於期內為集團的主要收益貢獻來源。紅葡萄酒與白葡萄酒產品的銷售收入分別佔集團整體收入約41%及54%。期內，紅葡萄酒產品和白葡萄酒產品的毛利率分別為38%及39%。本集團積極求新，聚焦「5+4+N產品戰略」，其中「N」代表集團推出N項需求定制，不斷開拓創新產品，以滿足中國不同類型消費群體的多元化需求。於回顧期內，本集團繼續推出新產品及進行產品升級，以更好地滿足不同葡萄酒口味及不同消費能力的消費者，旨在激發品牌活力，並鞏固王朝作為國產葡萄酒代表的品牌形象。本集團以「王朝」品牌產銷超過100種葡萄酒產品，迎合中國葡萄酒市場大眾市場分部不同消費者群的各項需求和喜好。於回顧期內，本集團推出中高端新品－王朝乙巳蛇年生肖紀念乾紅葡萄酒，與中國生肖文化相融合，引領「國潮風」，以年輕化的視覺語言呈現生肖文化，吸引潛在消費者。於本期間，本集團持續加強與酒業協會的合作，開展「龍行高校」等活動，進一步擴大品牌在年輕族群中的認知度與美譽度。基於其現有的優質產品，本集團繼續推出新產品並推進產品升級。本集團於二零二五年三月在第112屆全國糖酒商品交易會上推出天陽茶酒系列、王朝百馥VSOP白蘭地等新品，以進一步完善其產品矩陣，為消費者提供多元的消費選擇。該系列茶香葡萄酒突破傳統葡萄酒的局限，以「茶酒融合」為核心理念，憑藉獨特的釀造工藝迅速獲得市場目光。這款茶香葡萄酒以白酒為基調，融合茉莉花及普洱茶的芬芳，在傳統的氣泡酒領域中，創造出一種全新的東方韻味。在全國糖酒商品交易會期間，本集團亦舉辦品酒會，王朝天夏酒莊的新品憑藉獨特的風味和精湛的釀造工藝，贏得業界的好評。除致力於中國核心葡萄酒業務外，本集團亦將通過新設立的合資公司，拓展新的酒類飲料領域，如醬香型白酒、黃酒及特種黃酒－陳皮酒，以實現收入來源的多元化。王朝醬香型白酒產品，即「漢」、「唐」、「宋」、「明」，已於天津核心市場新推出並得到熱烈迴響，並將於下半年進一步戰略推廣至其他地區。醬香型白酒產品滿足不同消費習慣的客戶群體的需求，並為本集團業務作出貢獻。未來，醬香型白酒產業的發展及擴張及客戶群體水平的持久提升，必將有效推動王朝葡萄酒及相關產品銷售的增長，從而提升我們的行業影響力及品牌知名度。對於黃酒項目，經規劃後，正於二零二五年下半年在江蘇建設一座儲罐容量為3,000噸黃酒及特種黃酒－陳皮酒的生產廠房。於建設工程竣工後，本集團將能夠生產特種黃酒－東台陳皮酒，讓本集團可有效擴展產品品類，把握中國黃酒行業的發展機遇，實現酒業高質量發展的重大戰略舉措。電商銷售方面，於回顧期內，本集團的電商團隊於傳統電商平台全面運營在線商店銷售產品，例如京東商城、天貓商城及拼多多，以及通過興趣電商平台（包括小紅書app、快手app及抖音app）全面創新品牌、品類、業務體系、流程和模式。本集團的自主品牌傳播使其可繼續獲得主流消費群體和圈子的關注，並提高本集團面向年輕消費者的產品的有效市場滲透率。同時，電商團隊積極培養電商直播人才，以進一步擴大其銷售渠道及建立新客戶群。此外，於回顧期內，本集團在大型葡萄酒品鑒大賽中屢獲殊榮。在多個獎項中，「王朝錦邑桶藏12年XO白蘭地」榮獲二零二五年國際葡萄酒與烈酒大賽（「IWSC」）中的銀獎。該比賽被視為葡萄酒和烈酒質量的國際評價標準。王朝百馥VSOP白蘭地、金王朝馬瑟蘭乾紅葡萄酒以及天陽茶酒系列亦於中國酒業協會舉辦的「二零二四年青酌獎」各類別評選中獲獎。「王朝夢園白葡萄酒」亦以其卓越的酒質榮獲二零二五年春季FIWA法國國際葡萄酒大獎賽中國區金獎。此外，「王朝傳承系列－乾紅葡萄酒」於同一比賽中榮獲金獎。該等葡萄酒因其酒香優雅、酒體順滑和口感圓潤從眾多參賽作品中脫穎而出，並在比賽中獲得獎項，向國家及世界展示了王朝葡萄酒的魅力和實力。王朝主席萬守朋先生總結︰「展望二零二五年下半年，本集團將繼續聚焦市場和消費者需求，並通過技術創新提升產品質量。同時，本集團將繼續創新營銷策略，激發品牌活力，進一步擴大王朝產品的市場份額，加強王朝品牌作為國產葡萄酒代表的形象，並為中國葡萄酒行業樹立標桿，將王朝美酒風尚帶給更多的中國消費者。本集團將繼續通過產品品類及消費場景的創新，以及跨行業合作，積極開拓新的營銷前景，以提升銷量，藉此支持國家擴大內需及釋放消費增長潛力的工作。」關於王朝酒業集團有限公司王朝酒業集團有限公司於2005年1月26日在香港聯合交易所有限公司主板上市，股份代號00828。成立於1980年，王朝爲中國優質葡萄酒生産商，主要生産及銷售「王朝」商標的葡萄酒産品，是中國第一家中外合資的釀酒企業，主要股東包括天津食品集團有限公司及法國葡萄酒巨頭人頭馬集團。集團產銷葡萄酒產品系列超過100種，及引入進口葡萄酒產品，為國內各消費層提供高質素及物超所值的葡萄酒。 Copyright 2025 亞太商訊 via SeaPRwire.com.

香港，2025年8月28日 - (亞太商訊 via SeaPRwire.com) - 8月27日，澳優乳業股份有限公司（股份代號：1717.HK，以下簡稱"澳優"或"公司"）發布2025年上半年業績公告。公告顯示：2025年1-6月，澳優實現營業收入約人民幣38.87億元，同比增長5.6%；實現EBITDA（息稅折舊及攤銷前利潤）約人民幣3.98億元，同比增長29.7%；歸屬于母公司權益持有人應占利潤約人民幣1.81億元，同比增長24.1%，實現營收利潤持續韌性雙增長。 公告表示，2025年上半年，面對複雜多變的全球經濟形勢及競爭加劇的中國嬰配粉市場環境，澳優穩步推進"奶粉+營養品"全家營養戰略，進一步打造産品力、品牌力、渠道力、數智力及組織力，在消費者的信任、社會各界的支持和全體澳優人的共同努力下，營收、利潤繼續保持雙增長趨勢，以堅韌不拔的毅力和穩健扎實的步伐邁向高質量發展新階段。分版塊看，澳優自有品牌奶粉業務實現整體營收約人民幣28.26億元。其中，羊奶粉業務實現收入18.65億元，同比增長3.1%，"領頭羊"地位持續穩固，尼爾森IQ數據顯示截至6月底公司羊奶粉市場占有率同比提升2.8個百分點至30.4%；在2024年中國進口嬰幼童羊奶粉市場銷售量份額及銷售額份額均高達84%，已連續7年在中國進口嬰幼童羊奶粉市場份額超6成。【1】與此同時,弗若斯特沙利文經市場研究確認：2024年佳貝艾特羊奶粉銷量與銷售額全球第一。【2】牛奶粉業務實現收入約人民幣9.61億元。營養品業務實現收入同比增長7.0%，幷成功拓展至海外市場。分區域看，2024年羊奶粉中國業務實現收入約人民幣13.81億元；羊奶粉國際業務實現收入約人民幣4.83億元，同比大幅增長65.7%，國際業務多點開花，實現爆發式增長，在公司自有品牌配方羊奶粉業務總收入的占比進一步提升至25.9%。公告顯示，中東地區在2025上半年繼續保持澳優海外最大銷售市場的地位；北美地區收入同比提升逾138.7%，成為澳優海外市場第二大營收來源，獨聯體地區收入同比增長33.8%。澳優在公告中表示，羊奶粉業務海外市場在過去兩年保持高雙位數複合增長率的基礎上，于上半年再攀高峰，實現同比增長65.7%；營養品業務戰略布局全面起勢，成為驅動公司發展的重要動力。數據來源：【1】尼爾森IQ進口嬰幼童羊奶粉零售追踪數據；時間段：2018年-2024年，連續7個年度；渠道範圍：上海、江蘇、浙江、安徽、河南、廣東、湖南、湖北、福建、江西、北京、天津、黑龍江、吉林、遼寧、山東、山西、河北、陝西、四川、重慶、貴州、雲南、廣西的城市母嬰渠道。【2】弗若斯特沙利文Frost & Sullivan《全球羊奶粉市場獨立研究報告》（2025年4月）。基于對全球羊奶粉市場的研究，對2024年全球範圍內主要羊奶粉品牌的銷量以及銷售額進行研究分析後做出的確認，調研數據覆蓋2024年1月至12月。 Copyright 2025 亞太商訊 via SeaPRwire.com.

- 华堂宁(R)銷量同比增長108%，淨銷售額同比增長112%。醫保覆蓋持續擴大，二級和三級醫院處方量顯著增加，全面自主商業化成效顯著。- 與拜耳終止獨家推廣服務協議後，確認一次性遞延收入人民幣12.435億元，實現上半年盈利11.839億元，公司在業績期內首次實現盈利。- 在中國開展涉及80個中心和2000名2型糖尿病患者的真實世界研究，進一步證明多格列艾汀的廣泛適用性和安全性。- 多格列艾汀75mg（商品名：MYHOMSIS(R)，華領片TM）在香港遞交註冊申請，加速佈局大中華區及東南亞市場。- 毛利率顯著提升，生產規模與運營效率持續優化。上海，2025年8月28日 - (亞太商訊 via SeaPRwire.com) - 華領醫藥（"公司"，香港聯交所股份代號：2552）宣佈公司及其附屬公司截至2025年6月30日止六個月（"報告期"）未經審核的綜合業績，以及公司上半年業務進展與未來展望。報告期內，公司核心產品华堂宁(R)（多格列艾汀片）商業化加速，自主運營能力顯著提升，研發進展順利推進，財務表現實現突破性成長，為長期可持續發展奠定了堅實基礎。華領醫藥創始人兼首席執行官陳力博士表示："2025 年上半年是華領醫藥轉型發展的關鍵階段。全面接管华堂宁(R)商業化後，公司憑藉自主搭建的銷售團隊，實現了銷量與收入的翻倍增長，印證了新的商業模式的有效性。我們還在中國香港遞交了新藥上市申請，為多格列艾汀從中國走向東南亞乃至全球市場奠定了基礎。同時，多格列艾汀在真實世界研究中持續展現出廣泛的治療潛力，也在基礎研究中發現了糖尿病緩解、認知改善、血脂改善和增肌等方面的新證據，進一步鞏固了華領醫藥在GKA研發和治療領域的全球領先地位。未來，華領醫藥將繼續深耕糖尿病和整個代謝疾病領域，通過創新研發與市場拓展的雙輪驅動，讓中國原創新藥惠及更多全球患者。"業務亮點與運營進展商業化轉型成效顯著，銷售與利潤雙增長- 2025年1月1日起，公司終止與拜耳的獨家推廣服務協議，全面接管华堂宁(R)在中國的商業化運營。報告期內，在與2024年同期的單價保持一致的情況下，华堂宁(R)銷量達176.4萬盒，同比增長108%；淨銷售額達2.174億元，同比增長112%。憑藉強勁的商業執行力和不斷提升的運營效率，公司邁向盈利。華領醫藥已順利過渡到全面自主商業化階段，也印證了日益增長的市場需求和自主銷售團隊的高效執行力。- 2024年被納入中國國家醫保藥品目錄(NRDL)後，2025年华堂宁(R)繼續受益於廣泛的醫保覆蓋，二級和三級醫院的處方量顯著增加，有助於提高患者的可及性和長期使用率。- 由於生產規模擴大和成本效率的提升，公司毛利率提升至54.2%，高於去年同期的46.5%。- 在銷售額同比增長112%的情況下，報告期內公司銷售費用為6420萬元，與去年同期相比僅增長5%，報告期內銷售費用約占總收入的29.5%，顯著低於去年同期的59.5%。這是因為，2025年上半年銷售費用構成與2024年同期相比發生了顯著變化：由公司在中國承擔华堂宁(R)的獨家商業化責任而直接產生銷售費用，而無需再向原商業化合作夥伴支付推廣費用。這反映出公司顯著的盈利向好趨勢，也表明了公司的業務戰略，即通過控制與华堂宁(R)商業化直接相關的銷售費用，以及最大限度地提高生產效率，來優化盈利能力。- 與拜耳終止獨家推廣服務協議後，公司確認一次性遞延收入12.435億元，向自主驅動增長轉型。華領醫藥首次實現半年稅前利潤11.839億元，這是華領醫藥邁向可持續盈利的關鍵里程碑。- 截至2025年6月30日，現金餘額為10.228億元，為公司未來的研發和商業化舉措奠定了堅實基礎。臨床研究持續深入，新證據支撐治療潛力- 公司正在推進多項上市後研究，以評估多格列艾汀在不同患者群體中的長期安全性和有效性，包括單藥治療以及與其它已經獲批的熱門降糖藥，如GLP-1受體激動劑、胰島素、DPP-4抑制劑和SGLT-2抑制劑的聯合用藥。這些研究正在為血糖控制、認知改善和糖尿病緩解潛力等提供新的臨床依據。- 公司正在開展多格列艾汀上市後真實世界研究（BLOOM），在全國80家中心納入2000例2型糖尿病患者，目前已完成1000余例患者的1年隨訪。在真實世界環境中，BLOOM研究進一步證明了多格列艾汀的廣泛適用性和安全性。在臨床用藥中，接受多格列艾汀治療的患者往往存在多種合並症，包括各種心血管和腎臟疾病等，並且正在接受多種伴隨藥物治療。除二甲雙胍外，超過60%的患者在使用多格列艾汀的同時，還聯合使用了SGLT-2抑制劑、胰島素、GLP-1受體激動劑或DPP-4抑制劑等其它降糖藥。無論是單藥治療還是聯合用藥，多格列艾汀普遍表現出良好的耐受性，安全性特徵也與先前的臨床研究資料保持一致。- 在2025年美國糖尿病協會（ADA）科學年會上，公司公佈了多格列艾汀的新研究資料，進一步闡明其作為疾病修飾療法的作用機制，關於多格列艾汀作為GKA藥物的新作用機制的相關成果已發表於《糖尿病》（Diabetes）雜誌上。研發管線與未來展望- 公司已在中國香港提交多格列艾汀75mg（商品名：華領片TM，MYHOMSIS(R)）的註冊申請，旨在擴大在大中華區和東南亞的業務版圖。- 公司正在通過開發二甲雙胍和多格列艾汀的固定複方製劑拓展產品管線，用於服用高劑量二甲雙胍（>每日1500mg）仍無法控制血糖的患者，此前的DAWN臨床研究顯示，多格列艾汀聯合二甲雙胍用藥可使患者的糖化血紅蛋白（HbA1c）降低超過1%，餐後血糖降低超過5mmol/L，低血糖發生率僅為0.8%。該血糖控制水準表明，多格列艾汀-二甲雙胍固定劑量複方製劑作為口服降糖藥具有強大的潛在需求。2025年8月，公司已完成IND前資料提交，預計於2026 年初啟動生物等效性（BE）研究。- 通過收集真實世界證據以及在動物模型中開展概念驗證研究，公司正在推進多格列艾汀與GLP-1受體激動劑、DPP-4製劑和SGLT-2抑制劑的聯合用藥。多格列艾汀與這些藥物之間的協同作用有望將其適應症擴展到肥胖症、代謝相關脂肪性肝炎（MASH）等其它代謝紊亂疾病領域。- 公司將繼續加強與國際領先的研究機構的合作。由華領醫藥支持的一項研究者發起的I 期臨床研究正在賓夕法尼亞大學進行，旨在評估多格列艾汀在囊性纖維化相關糖尿病（CFRD）患者中的療效和安全性，該試驗已獲得美國食品藥品監督管理局（FDA）的批准。- 公司將繼續致力於開發糖尿病預防、代謝紊亂相關神經退行性疾病領域的治療機遇，最終找到一種新的方法來延長人類的健康壽命。- 公司將繼續投資於數字技術平台，以在各個職能部門之間創造協同效應，並利用人工智慧技術提升品牌機遇。- 公司將繼續自主推進多格列艾汀和第二代GKA的研發，並與學術和戰略合作夥伴共同開展相關工作。公司正在推進多格列艾汀在香港的註冊，並繼續在東南亞和"一帶一路"國家尋求合作夥伴。基於美國I期單劑量遞增研究的初步成功，公司計劃於2025年底或2026年初啟動多劑量遞增I期研究，從而繼續推動第二代GKA在全球市場的業務發展。財務摘要截至2025年6月30日- 公司銀行結餘及現金約人民幣10.228億元- 總營收約2.174 億元，同比增長112%，华堂宁(R)銷量達176.4萬盒，同比增長108%- 毛利約1.178億元，同比增長147%，毛利率約54.2%，同比增長7.7個百分點- 其他收入約12.546億元，其中拜耳一次性遞延收入為12.435億元- 總開支約1.871億元，其中研發開支約6580萬元- 稅前利潤約11.839億元，同比增長932%前瞻性聲明本文包含有關華領醫藥以及產品未來預期、計劃和前景的陳述。該等前瞻性陳述僅與本文作出該陳述當日的事件或資料有關，可能因未來發展而出現變動。除法律規定外，於作出前瞻性陳述當日之後，無論是否出現新資料、未來事件或其他情況，我們並無責任更新或公開修改任何前瞻性陳述及預料之外的事件。請仔細閱讀本文並理解，由於各種風險、不確定性或其他法定要求我們的實際未來業績或表現可能與預期有重大差異。關於華領華領醫藥（"本公司"）是一家總部位於中國上海的創新藥物研發和商業化公司，在美國、中國香港設立了公司。華領醫藥專注於未被滿足的醫療需求，為全球患者開發全新療法。華領醫藥匯聚全球醫藥行業高素質人才，融合全球創新技術，依託全球優勢資源，研究開發突破性的技術和產品，引領全球糖尿病醫療創新。公司核心產品华堂宁(R)（多格列艾汀片）以葡萄糖感測器葡萄糖激酶為靶點，提升2型糖尿病患者的葡萄糖敏感性，改善患者血糖穩態失調。2022年9月30日，华堂宁(R)已獲得中國國家藥品監督管理局（NMPA）的上市批准，用於單獨用藥或者與二甲雙胍聯合用藥，治療成人2型糖尿病。對於腎功能不全患者，無需調整劑量，是一款可用於腎功能損傷的2型糖尿病患者的口服降糖藥物。詳情垂詢華領醫藥網址：www.huamedicine.com投資者電郵：ir@huamedicine.com媒體電郵：pr@huamedicine.com新聞免責聲明本材料，如為上下文論述的準確性和完整性，提及在中國上市的產品相關資訊的，特別是標識或要求，應遵循中國監管機構批准的相關檔。另外，相關資訊不應被解讀為對任何藥物或者診療方案的推薦或者宣傳，亦不應替代任何醫療衛生專業人士的醫療建議，涉及醫療的相關事宜務必諮詢醫療衛生專業人士。 Copyright 2025 亞太商訊 via SeaPRwire.com.

香港，2025年8月28日 - (亞太商訊 via SeaPRwire.com) - 2025年8月，北京--首程控股有限公司（0697.HK，以下簡稱「首程控股」）、北京首程機器人科技產業有限公司（以下簡稱「首程機器人」）、阿爾特汽車技術股份有限公司（300825.SZ，以下簡稱「阿爾特」）、北京阿爾瑞特智能機器人科技有限公司（以下簡稱「阿爾瑞特」）正式簽署戰略合作框架協議。四方將充分發揮各自優勢，圍繞機器人產業的技術創新、應用落地、產業鏈協同與人才培養，展開全方位合作，推動「機器人+汽車」應用新業態加速發展。一、產業背景：機器人進入應用落地加速期當前，全球機器人產業正處於高速發展階段，國家戰略和政策密集出台。8月26日，國務院正式發佈《國務院關於深入實施「人工智能+」行動的意見》（國發〔2025〕11號），明確提出要推動人工智能與經濟社會各行業各領域的廣泛深度融合，加快形成人機協同、跨界融合、共創分享的智慧經濟和智慧社會新形態。在這一國家戰略指引下，機器人產業正從「技術突破」邁向「應用落地」。汽車與機器人作為兩個高度契合的產業，正逐漸呈現跨界融合趨勢。此次首程控股與阿爾特集團的合作，將在政策東風與市場需求的雙重驅動下，為機器人在研發、製造、交通和出行服務等關鍵環節的應用注入新動能。阿爾特是中國汽車設計領域的領軍企業，也是A股市場唯一的獨立汽車設計上市公司，具備整車研發設計與核心零部件製造的全流程服務能力，並踐行「技術+供應鏈」的國際化戰略。據公開資訊，公司累計服務超過80家客戶，參與開發近500款車型，客戶涵蓋一汽、東風、北汽、吉利、新勢力品牌與合資企業等主機廠類型。這意味著阿爾特在汽車產業鏈中擁有深厚的主機廠資源與交付能力。與此同時，阿爾特通過控股子公司--北京阿爾瑞特智能機器人科技有限公司，已正式開闢機器人新賽道。阿爾瑞特致力於打造一體化研發設計與仿真訓練平台，能夠為多場景機器人開發提供從仿真、測試到優化的全流程支撐；目前已啟動輪式機器人、水下機器人、鑽井機器人和寵物洗護機器人等多個研發項目，體現了其跨場景研發和產業協同的潛力。阿爾瑞特的加入，使本次合作不僅侷限於傳統汽車設計層面的協作，更在機器人研發、仿真與汽車產業化融合方面提供了重要支撐。與阿爾特及阿爾瑞特的合作，將幫助首程把機器人技術深度嵌入汽車產業鏈的核心環節，如整車製造、智能裝配與產線測試，使機器人真正進入產線、加速產業應用。這一戰略合作不只是一種技術對接，更是借助阿爾特在主機廠客戶群體中的資源網絡，將機器人場景從「隔壁展示」一步推向「生產車間」，連接研發驗證與規模化交付的關鍵路徑。二、合作重點：研發突破與應用落地並舉在國務院「人工智能+」行動政策引領下，四方將立足「技術研發-產業應用-生態共建」全鏈條，協同推進產業創新，重點在以下方向展開合作，助力機器人與汽車深度融合：（一）技術創新與聯合研發四方將聯合建設機器人一體化研發與仿真平台，借鑒汽車行業的完整研發體系，重點在運動控制、結構優化、車規級零部件和規模化製造等關鍵環節實現突破。同時，依託 NVIDIA Isaac/Omniverse 技術，共同打造一體化仿真訓練平台，不僅支援機器人在汽車研發、製造和測試中的應用模擬，還可開展智能駕駛車輛與物流機器人協同作業等跨場景模擬。雙方還將建立數據與成果共享機制：首程控股提供來自交通、出行等運營環節的數據資源，阿爾特輸出汽車工程和機器人研發經驗，形成從仿真-研發-驗證-產線應用的完整閉環。（二）優先採購與協同機制在研發設計、仿真訓練、整機和零部件供應等環節，四方將實行優先採購機制，在同等條件下優先選擇協議方為合作夥伴。首程控股與首程機器人重點提供產品推廣、代理及配套服務；阿爾特與阿爾瑞特聚焦於技術研發、工程化驗證和客製化整機開發。各方將協同推進機器人本體二次開發，確保機器人產品在汽車生產線、智能裝配和產線檢測等場景下實現最佳適配。通過分工協作，形成產品供給-技術創新-應用反饋的互補格局，加快成果轉化，提升商業化效率。（三）人才培養依託首程、阿爾特及其合作夥伴的科研與產業平台，四方將聯合開展技術攻關、仿真訓練與應用試點，為科研人員和工程師提供跨行業、跨場景的實踐環境。同時，定期舉辦技術研討會和產業論壇，邀請行業專家和上下游企業參與，建立聯合人才培養機制，打造一批兼具汽車工程背景與機器人產業化實踐經驗的青年科研人才，夯實長期發展的人才基礎。（四）拓寬發展空間四方將深度對接國家「人工智能+」與機器人產業發展戰略，重點推動「機器人+汽車」在研發、製造、測試和出行服務環節的規模化應用。在此基礎上，合作還將逐步延展至智慧交通、智能製造、醫療健康、教育、公共服務等更廣闊的領域，涵蓋機器人及核心零部件的設計、研發、生產、測試和商業化服務。同時，結合資本與產業的聯動，推動產業鏈上下游協同升級，最終形成從研發驗證到規模化應用的全鏈條閉環，打造具有示範效應的「機器人+汽車」應用矩陣，實現互利共贏和長期價值創造。三、戰略意義：打造機器人應用新標杆機器人產業的最大價值在於應用落地，而「機器人+汽車」正是最具潛力和爆發力的應用方向之一。從整車研發到智能製造，從交通調度到智慧出行，機器人將在汽車全產業鏈環節展現巨大價值。首程控股憑藉資本平台、生態資源與產業基金優勢，已投資宇樹科技、銀河通用、松延動力、星海圖、加速進化等國內頭部企業，具備前沿技術的整合能力；首程機器人則與上百家上下游優質企業建立合作，成為國內鏈接資源最全面的平台之一。阿爾特與阿爾瑞特則將汽車領域成熟的工程體系遷移至機器人研發與產業化。雙方優勢疊加，構建起「研發-迭代-應用-規模化」的完整路徑。此次攜手阿爾特，將進一步把首程的場景資源與產業生態，與阿爾特在整車研發、工程化能力與產業化經驗深度結合。未來1-2年，合作將聚焦「機器人+汽車」的深度融合，率先在汽車研發、生產製造、智慧交通與出行服務等環節實現規模化應用示範，推動機器人從實驗室走向產業化、規模化，加速形成具備示範效應的「機器人+汽車」應用矩陣。與此同時，合作也將放眼國際市場，推動中國方案走向全球，培育新質生產力，為股東創造長期價值。Posted by All Way Success Company Limited for Shoucheng Holdings www.shouchengholdings.com [HKSE:0697, FRA:SHVA, OTCPK:SHNHF] Copyright 2025 亞太商訊 via SeaPRwire.com.

香港，2025年8月29日 - (亞太商訊 via SeaPRwire.com) – 天能動力國際有限公司(「公司」，連同其附屬公司，統稱「集團或天能」）（股份代號：00819.HK)公布截至2025年6月30日止六個月（「報告期內」）之中期業績。2025年上半年，天能堅持戰略引領、改革破局的總體思路，統籌推進實業、科技、資本三輪驅動戰略。在鞏固鉛蓄電池業務核心競爭力的同時，加速海外市場開拓，推動新能源電池業務從積累轉向釋放，深化電池循環體系的縱深建設，驅動業務全景化、可持續發展。報告期內，集團實施聚焦主業、主動收縮貿易業務戰略，實現制造業營業收入約人民幣211.68億元，較去年同期基本持平，占整體營業收入比例提升至約87.5%；實現貿易業務營業收入約人民幣30.24億元，較去年同期下降約89.47%，占整體營業收入比例下降至約12.50%。製造業中，高端環保電池業務穩築基本盤，為戰略轉型提供堅實的財務後盾。新興業務高速增長，其中，鋰離子電池業務取得營業收入約5.01億元，較去年同期躍升174.58%。報告期內，集團實現毛利額約人民幣25.37億元，較去年同期基本持平；經營現金流釋放躍升，由去年同期約人民幣1.62億元淨現金流出轉變至約人民幣8.91億元淨現金流入。綜上，2025年上半年，在複雜外部環境下，天能展現出強大經營韌性、發展動能和戰略執行力。國際化進程加速 海外市場拓展成果顯著國際化布局是集團提升全球競爭力、實現增量跨越的重要戰略支點。2025年上半年，海外業務呈現突破性增長，市場反饋持續向好，實現營業收入約人民幣2.26億元，較去年同期增長約75.39%。報告期內，集團以當地需求為導向，結合海內外產業資源加速國際市場開拓，於泰國、越南、土耳其等地配置本地運營團隊，發展數十家授權經銷商，銷售網絡覆蓋亞太、歐美、中東非各地區主要國家。越南生產基地建設有序推進，組裝基地產能全面釋放，為區域深耕奠定基礎。針對性開發本地化產品，滿足差異化需求；重點建設本地化渠道與運營團隊；同步推進“服務出海”戰略，系統性構建本地化服務標準體系。優化全球供應鏈，釋放增長動能。主業穩中見韌 蓄勢動能長青 報告期內，集團在複雜外部環境與產業結構再平衡的背景下，堅持「穩中求進，以進促穩」的經營節奏。高端環保電池業務表現堅實，上半年取得營業收入約人民幣182.92億元，為集團穩健續航持續注入動力。高端環保電池是集團基於研發與工藝創新打造的密封型免維護鉛蓄電池，深度適配電動輕型車市場需求，憑借其綜合成本及性能優勢，亦廣泛應用於備用電源、汽車電池與電動特種工業動力電池等領域。集團秉持核心業務優勢，深化智能制造升級、精進運營管理體系、鞏固銷售渠道網絡，驅動產品質量持續提高與綜合市場競爭力不斷增強，強化鉛蓄電池業務在複雜市場環境下的發展韌性。報告期內，集團通過智能制造體系應用與設備技術改造升級，有效提升制造效能與供應鏈保障能力，成本管控成效逐步顯現；依托電池技術迭代驅動產品性能升級，圍繞電動輕型車、數據中心、汽車起動啟停與工業動力等重點場景，形成差異化產品矩陣；驅動以用戶價值為核心的服務體系升級，深度整合傳統經銷網絡與創新數字生態。深化多元技術路線 加快業務增長新動能2025年上半年，集團錨定新能源業務發展方向，圍繞鋰離子電池、固態電池、氫燃料電池、鈉離子電池等多技術路徑，系統推進研發攻關、智能制造與場景拓展，加快培育業務增長新動能。集團鋰離子電池主要聚焦儲能與低速動力等領域。報告期內，集團儲能與低速動力業務實現量的躍升與質的改善，工業電池及駐車空調電池等細分市場增量空間得以拓展，產能利用率明顯提升，整體營收顯著增長，經營質效明顯改善，取得營業收入約5.01億元，較去年同期增長約174.58%。集團固態電池研發取得階段性進展，重點突破高比能、長循環及高倍率三大方向，與頭部兩輪車企業建立戰略合作關系，並在低空飛行器領域與相關企業推進解決方案驗證。集團在氫燃料電池持續投入，擁有全鏈條研發體系和專家團隊，產品性能先進，在兩輪車、公交、重卡及特種機械等場景推進示範驗證，並與上下遊合作夥伴共同構建應用生態。集團同步推進鈉離子電池技術與應用布局，報告期內圍繞汽車起動啟停與儲能等應用場景開展低溫與循環壽命等關鍵指標驗證，保持穩健的產業化節奏。通過多技術路徑的協同，遵循「技術攻堅—場景驗證—方案化交付」的推進節奏，集團新能源電池業務增長動因正由點式驗證向鏈條釋放有序過渡，業務動能得到紮實支撐。夯實循環體系 強化產業協同新動能集團專注於電池產業，系統構建覆蓋生產、回收、再利用的全生命周期產業鏈，形成鉛蓄電池和鋰離子電池雙軌循環產業體系，實現資源高效再生利用。報告期內，集團可循環產業實現對外營業收入約人民幣18.00億元，較去年同期增長約15.82%。作為國內循環產業的領先企業，集團著眼於構建兼具前端觸達能力與後端處理效率的高效回收網絡，以規模化的處置能力和業務協同優勢推動廢舊電池資源有效利用，關鍵材料回收率居於行業前列。報告期內，集團持續貫通回收、處置與再利用全流程，提升鉛蓄電池回收渠道整合力與運營精度；強化鋰離子電池回收差異化路徑布局，深化核心區域與重點場景資源聯動。集團通過深挖技術潛能與優化系統表現，逐步釋放循環體系的規模優勢與經濟價值，為產業注入持久動能。展望未來，天能將以技術革新驅動產業升級，以數智化賦能運營增效，以生態協同重塑價值鏈體系，以全球化布局開拓增量空間，鞏固鉛蓄電池核心主業優勢，加快推進鋰離子電池、固態電池等新能源電池的研發、應用與市場開拓，強化電池回收與資源再生能力，提升產業鏈一體化水平與協同效率。天能將同步加速海外市場布局與本地化經營能力建設，向制造與服務體系延伸，構建發展為具備長期競爭力和全球視野的新能源電池產業格局企業。天能將持續推動企業價值與社會價值深度融合、共同成長，打造可持續、高質量增長的創新範式。關於天能動力國際有限公司天能動力國際有限公司及其附屬公司創立於一九八六年，總部設於中國，憑借完善的制造體系與技術優勢，發展成為新能源電池行業領先企業及輕型電動車電池領域龍頭企業，二零零七年於香港聯合交易所有限公司主板上市（股份代號：00819.HK）。曆經近四十載發展，集團以鉛蓄電池為核心主業，深耕電動輕型車動力電池市場，並拓展至備用電源、汽車電池與工業動力電池等多元領域。集團為全面布局未來新能源生態，在堅守主業優勢的基礎上，積極推進鋰離子電池、固態電池、氫燃料電池及鈉離子電池的研發、生產與銷售，以多技術路線產品矩陣覆蓋多元新能源應用場景，並同步構建循環經濟產業鏈，依托廢舊鉛蓄電池與廢舊鋰離子電池循環利用業務，推動資源高效再生。 Copyright 2025 亞太商訊 via SeaPRwire.com.

HONG KONG, Aug 29, 2025 - (ACN Newswire via SeaPRwire.com) - Tianneng Power International Limited (the “Company”, together with its subsidiaries, collectively referred to as the “Group” or “Tianneng”), (Stock Code: 00819.HK) releases its interim report for the six-month period ended 30 June 2025.In the first half of 2025, adhering to the Group’s vision of Strategic Guidance and Reformation Breakthrough, Tianneng coordinated the three-wheeled strategy of Industry, Technology, and Capital. While solidifying the core competency of the lead-acid battery business, the Group also accelerated the expansion of overseas markets, released the Group’s built-up potential in new-energy battery, deepened the vertical construction of the battery recycle system, and drove the diversification of products and sustainability.Within the reporting period, the Group made a strategic pivot to reduce the trade business, achieved RMB 21.168 billion in revenue for the manufacturing business, which was stable compared to the same period in 2024, accounting for approximately 87.5% of the total revenue within the sector. In terms of the trade business, the Group realized an overall revenue of RMB 30.24 billion, which represented an 89.47% decrease from the same period of 2024. Within The manufacturing sector, the high-end eco-friendly battery business remained stable, providing a resilient financial support for the Group. The emerging businesses experienced significant growth, among which the Li-ion battery business achieved a revenue of RMB 0.501 billion, representing a 174.58% growth from the same period of 2024. Within the reporting period, the Group achieved a gross profit of RMB 2.537 billion, which is stable compared to the same period of 2024. In terms of operating cash flow, the Group achieved RMB 0.891 billion of net inflow, compared to a net outflow of RMB 0.162 billion in the same period of last year. Overall, in the first half of 2025, Tianneng demonstrated strong resilience, developmental momentum, and strategic commitment in a complex external environment.Internationalisation Accelerated, Overseas Expansion Bore FruitsInternational expansion is a vital fulcrum of the Group in strengthening global competitiveness and achieving incremental leaps. In the first half of 2025, the overseas business experienced remarkable growth with continuous positive feedback, achieving a revenue of RMB 0.226 billion, representing a 75.39% growth from the same period of 2024.Within the reporting period, guided by local demands, the Group accelerated its overseas expansion with global industrial resources, and set up operational teams in countries such as Thailand, Vietnam, and Turkey while developing a sales network in major areas including the Asia-Pacific, Europe, North America, the Middle-East and Africa. In addition, the Group’s production base in Vietnam is being constructed in an orderly manner while the capacity of the assembly base is robustly released, laying the groundwork for future developments in the region. The Group has developed customised products based on specific local demands and emphasised building localised operational teams, while advancing its “Overseas Service” strategy, and systematically constructed localised standards. With these developments, the Group was able to optimise its global supply chain and release future growth potentials.Core Business Stable and Resilient, with Promising Growth MomentumWithin the reporting period, the Group pursued a path of “Stability and Growth Duality” under a complex external environment and industrial structure re-balancing. The high-end eco-friendly battery business demonstrated resilience, achieving a revenue of RMB 18.292 billion, providing the vital financial stability for the Group. The high-end eco-friendly batteries are sealed, maintenance-less lead-acid batteries built with the Group’s innovation in design and manufacturing, highly adapting to the demands of the light electric vehicle market, with their cost and performance superiority, are also widely utilised in various fields, including backup power supplies, automobile batteries, and special-purpose industrial power batteries.The Group solidified its competencies in the core business, upgraded its intelligent manufacturing capabilities, improved the operational management system, consolidated its sales network, drove product quality and comprehensive market competitiveness growth, and fortified the resilience of lead-acid batteries in a complex market environment. Within the reporting period, the Group was able to effectively upgrade its manufacturing efficiency and supply-chain resilience through utilising intelligent manufacturing systems and equipment technology upgrades, while demonstrating effective results in cost management. Through the evolution of battery technologies and product upgrades, the Group constructed a differentiated product matrix targeting major fields of usage such as light electric vehicles, data centres, automobile start-stop batteries, and industrial power batteries,driving a service system upgrade with user value at its core, and organically merged the traditional sales network with an innovative digital ecosystem.Solidifying the Diversity of Technological Road-maps and Accelerating New Business Growth In the first half of 2025, the Group committed to the development of new-energy businesses, including Li-ion batteries, solid-state batteries, hydrogen fuel cells, and sodium-ion batteries, and systematically drove innovative breakthroughs, intelligent manufacturing upgrades, user-scenario extensions, and fostered new business growth. The Group’s Li-ion batteries business mainly targets power storage and low-speed power. Within the reporting period, the Group’s power storage and low-speed power business achieved major improvements both in terms of quality and quantity. Specific markets, such as industrial batteries and automobile A/C batteries, also saw improvements in market volume. Overall, the capacity utilisation of the Group’s new-energy business was significantly enhanced, with remarkable improvements in operational efficiency and revenue, RMB 0.501 billion, a 174.58% increase from the same period of 2024.The Group’s solid-state battery also achieved intermittent success within the three dimensions of high energy density, cycle longevity, and high-rate performance. The Group also formed strategic collaborations with industry leaders in the two-wheeled vehicle market and carried out solution testing with partners targeting the low-altitude flying vehicle market. The Group continued its investment in hydrogen fuel-cells with a full-chain R&D system and an expert team, with advanced products, began testing in user-scenarios such as two-wheeled vehicles, public transportation, heavy trucks, and special-purpose machinery, and collaborated with upstream and downstream partners in constructing an application ecosystem. The Group also spearheaded the development and application of sodium-ion battery technology, and conducted experiments for key metrics such as low-temperature and cycle longevity testing for scenarios such as power storage and automobile start-stop battery in a steady manner. Through the multi-roadmap approach, and the “technology breakthrough - user scenario verification - solution delivery” process, the Group’s new-energy business growth is gradually and steadily shifting from individual verification to chain-release, firmly supporting the business momentum.Strengthening the Recycling System and Fortifying Industrial CollaborationThe battery industry is at the core of the Group’s business, which systematically constructed a full-life industry chain of manufacturing, recycling, and reusing, forming a two-railed industry system of lead-acid battery and Li-ion battery, achieving efficient recycling. Within the reporting period, the recycling business of the Group achieved a revenue of RMB 1.8 billion, a 15.82% increase compared to the same period of 2024.As a leader in the recycling industry in China, the Group is continuously building an effective recycling network with front-end reach and back-end efficiency, promoting the efficiency of waste battery recycling empowered by the collaborative effort of businesses at scale, and achieving a top-of-industry recycling ratio of crucial materials. Within the reporting period, the Group continued to enhance the granularity and precision of the recycling process from recycling, processing, and reusing, improve the differentiating system for Li-ion battery recycling, and improve the resource synergies at core regions and user scenarios. Through uninterrupted exploration of technological potential and system performance optimisation, the Group was able to gradually achieve scale advantage and economic value of the recycling system, injecting continuous momentum for the industry.Looking forward, Tianneng will drive industrial upgrades through technological innovation, empower efficient operation through digitisation, rebuild the value-chain system through ecological collaboration, and seek growth through internationalisation. The Group will solidify its competencies in the lead-acid market, accelerate the research, application, and market expansion process of new energy batteries such as Li-ion battery and solid-state battery. The Group will strengthen its capabilities in battery recycling, enhance the collaborative efficiency of industry-chain integration while expediting its expansion into overseas markets and optimising localised operation, from product to service, and develop into a new-energy battery company that is competitive with a global vision. Finally, the Group will promote the convergence between its company values and social values with a growth mindset and build a new paradigm of sustainable and high-quality growth.About Tianneng Power International LimitedTianneng Power International Limited and its subsidiaries (collectively referred to as “Tianneng” or the “Company”), founded in 1986 and headquartered in China, has developed into a leading enterprise in the new energy battery and the light electric vehicle battery industry with a comprehensive manufacturing system and technological advantage. Tianneng was listed on the Main Board of The Stock Exchange of Hong Kong Limited (Stock Code: 00819. HK) in 2007. After nearly four decades of development, Tianneng has established lead-acid batteries as its core business, focusing on the market of motive batteries for light electric vehicles, while expanding its product in automotive start-stop systems, backup power for communication base stations and other diversified scenarios. The Company is also advancing the R&D, production and sales of lithium-ion batteries, hydrogen fuel cells, sodium-ion batteries and solid-state batteries, offering multi-technology battery solutions for special industrial vehicles, energy storage systems and other applications. Additionally, Tianneng strengthens its recycling economy initiatives around its core operations. Through a dual-track system for lead and lithium recycling, the Company achieves efficient resource regeneration and reuse, building a comprehensive ecosystem for the new energy industry. Copyright 2025 ACN Newswire via SeaPRwire.com.

香港，2025年8月29日 - (亞太商訊 via SeaPRwire.com) – 領先的中國醫學運營服務供應商雲康集團有限公司（「雲康」或「集團」；股份代號：2325）公佈截至2025年6月30日止（「報告期」）之中期業績。集團以「一橫一縱」為主要經營策略，橫向輸出精益運營體系，推進醫聯體多模式合作，縱向聚焦專科方向上的醫檢聯合創新，加速新技術新產品轉化及應用推廣，同時以AI賦能醫聯體整體解決方案，推動AI在醫療場景的實際應用，持續強化臨床賦能價值，呈現強大的經營韌性。2025年上半年，受集採、醫保控費及行業競爭加劇等多方面因素影響，導致集團短期業績未達預期，然而集團始終堅持產品創新和模式創新，並進一步完善企業經營管理的機制和流程，堅持精益運營，整體經營取得明顯成效。報告期內，集團毛利率約為34.0%，較2024年度整體毛利率提升約4.4%；虧損淨額人民幣55.4百萬元，較上年同期減少56.1%，明顯收窄。此外，醫聯體共建業務板塊持續為集團第一大業務板塊，錄得收益人民幣180.3百萬元，佔總收益的57.6%，較上年同期提升約9.6%，在深度服務賦能醫聯體客戶方面成效顯著，為集團長期高質量發展奠定基礎。報告期內，集團診斷檢測服務錄得收益人民幣313.2百萬元。一橫一縱策略穩步實施，院企合作成效明顯「一橫」——輸出精益運營體系，深化醫聯體多模式合作雲康一直致力於發展「以專業化為基礎、標準化為核心、數智化為手段、協同化為目標」的醫聯體共建創新服務模式。報告期內，集團已為近450家醫聯體客戶提供不同臨床需求的多場景解決方案，包括AI+醫聯體數智化解決方案、醫學實驗室整體合作、區域╱病理中心解決方案、精準醫學中心解決方案、專科聯盟建設解決方案等多模式合作。透過發揮雲康優勢，協助各級醫療機構提升服務能力、外拓服務範圍，構建分級協同的醫療服務體系，促進區域分級診療發展。報告期內，雲康持續與頭部引領型醫院、各地區市縣級醫院展開深度合作，在市場競爭形勢日趨嚴峻的情況下，醫聯體共建業務板塊仍保持穩健發展，競爭優勢進一步鞏固。「一纵」——醫檢聯合創新平台打造科研創新強引擎集團始終聚焦「臨床需求」，不斷加強院企合作，首創性打造「醫檢聯合創新平台」，助力集團業務開拓及提升產品競爭力。報告期內，集團已與全國數十家頂級醫療機構開展醫檢聯合創新合作，累計成功開發出數十項針對呼吸道感染、中樞神經系統感染、泌尿系統感染、婦科感染、結核感染等多領域的不同感染症候群檢測產品，以及個性化用藥基因檢測產品，創新產品累計服務客戶近300家，檢測收益持續增長。報告期內，雲康與廣東省人民醫院先後上市呼吸道感染、中樞神經感染、侵襲性真菌感染等系列新panel產品，成功構建國內院企科研創新轉化標準化孵育模式和「1+N」醫檢協同網絡，此外，雙方在科研創新過程中，積累了豐富的臨床經驗，在數十位國內臨床、檢驗等多領域專家學者的積極參與和持續推動下，形成了《tNGS臨床規範化應用專家共識》，並於報告期內在國內檢驗頂級期刊《中華檢驗醫學雜誌》發佈。報告期內，雲康亦與國內頂尖醫院廣州醫科大學附屬第一醫院緊密合作，成功開發泌尿tNGS產品，推動尿路感染精準診療的臨床實踐。同時，雲康與暨南大學附屬第一醫院聯合打造「校院企聯合創新平台」，孵化和運營「精神疾病藥物基因檢測創新項目」，並成功開發出抗抑鬱藥物基因檢測、抗焦慮及鎮靜安眠藥物基因檢測產品。AI賦能醫聯體多模式解決方案，提質增效深化客戶服務報告期內，雲康全面接入DeepSeek，實現集團數字化平台部署。雲康以「AI+」與「精準診斷」為核心理念，將人工智能技術廣泛應用於旗下醫學實驗室的多技術平台。以AI技術與雲康病理診斷平台的深度融合為例，雲康病理檢測流程被極大壓縮，單切片AI診斷效率持續優化，實現智能、效率、質量三重提升。此外，透過部署智能化功能應用，雲康已實現智能在線客服、結果與報告高效審核等功能，全面優化醫檢服務的流程，提升客戶服務體驗和滿意度。在院企聯合研發新技術新產品過程中，借助AI大模型強大的數據分析、模型構建和智能預測能力，雲康AI技術從生信分析、報告解讀、疾病風險評估、創新產品研發轉化等多方面賦能產品創新研發，加速產品落地臨床。值得一提的是，雲康攜手潤達醫療、華為共同開發的醫療大模型「智雲」已重磅發佈，覆蓋了診前、診中、診後的全流程場景，將為臨床醫療服務全流程提供更加高效、便捷的支持和體驗。同時，雲康與潤達醫療簽署戰略合作協議，以強化「AI+IVD+醫療服務」在產業生態鏈之間的深度合作，並共同推動人工智能大模型在醫療端的發展與應用，為客戶提供數智化的醫療解決方案。未來，「智雲」醫療大模型將在雲康合作醫療機構中試點應用，並逐步推廣至全國，為醫聯體建設運營提質增效。未來展望2025年是「十四五」規劃的收官之年，國家推動優質醫療資源加快擴容下沉，促進區域佈局更加均衡，同時不斷加快醫聯體建設，推動其由「搭框架」向「高質量運營」升級。臨床治療亦正從「廣譜治療」邁向「精準化治療」新階段，行業增長潛力持續釋放。同時，AI技術持續賦能分級診療，行業將迎來發展新機遇。展望未來，雲康將繼續緊跟行業發展脈搏，以國家政策為導向，不斷強化臨床賦能價值，持續探索「產品創新+模式創新」雙輪模式，加速業務開拓，深度賦能醫學檢測服務，惠及更多居民。雲康集團有限公司（股份代號：2325）雲康集團是中國領先的醫學運營服務提供商，早於2008年雲康便開始面向各級醫療機構提供標準化的醫療診斷服務，透過利用自身專業的診斷能力以及覆蓋全國的醫聯體服務網絡，逐漸發展成為醫學運營服務的領先平台。雲康也是中國領先的醫聯體診斷服務供應商，提供涵蓋醫聯體診斷及診斷外包的全方位醫療健康服務。雲康向中國醫聯體內的合作醫院提供診斷檢測服務，透過現場診斷中心協助其提升臨床診斷能力。迄今為止，雲康已成功為來自全國近450家現場診斷中心提供專業服務，截至2025年6月30日，雲康合作的醫院分佈於中國31個省市。 Copyright 2025 亞太商訊 via SeaPRwire.com.

HONG KONG, Aug 29, 2025 - (ACN Newswire via SeaPRwire.com) - Yunkang Group Limited ("Yunkang" or the "Group"; Stock Code: 2325), a leading medical operation services provider in China, has announced its interim results for the six months ended 30 June 2025 (the "Reporting Period"). The Group adopted “one horizontal, one vertical” as its core business strategy: horizontally, it extended a lean management system to advance multi-mode collaboration among medical institution alliances; vertically, it focused on specialty-specific innovation in medical diagnostics to fast-track the translation and implementation of new technologies and products. Meanwhile, the Group leveraged AI to enhance the comprehensive solutions for medical institution alliances, promoted the practical application of AI in healthcare scenarios, and continuously strengthened the value of empowering clinical practices, demonstrating strong operational resilience.In the first half of 2025, due to multiple factors, including the centralized drug-procurement program, cost controls of medical insurance, and fierce market competition, the Group’s short-term results did not meet expectations. However, the Group remained committed to product and business model innovation, and further refined the mechanisms and processes of its operational management. By adhering to lean operations, the overall performance has achieved significant improvements. During the Reporting Period, the Group’s gross profit margin reached approximately 34.0%, representing an improvement of approximately 4.4% over the overall gross profit margin for 2024. The net loss amounted to RMB55.4 million, a significant decrease of 56.1% compared to the same period last year. The joint construction business remained the Group’s largest business segment, which recorded the revenue of RMB180.3 million, accounting for 57.6% of the total revenue, increased by approximately 9.6% as compared with the same period last year, achieving significant outcomes in empowering medical alliance clients through in-depth services, paving the way for the Group’s long-term high-quality growth. During the Reporting Period, the Group’s diagnostic testing services recorded revenue of RMB313.2 millionSteadily implementing “one horizontal, one vertical” strategy, with notable achievements in hospital-enterprise partnerships“One horizontal” ——Extending lean management system to deepen diverse forms of collaboration within medical institution alliancesYunkang has been committed to developing an innovative service mode for the joint construction of medical institution alliances featuring “professionalism as the foundation, standardization as the core, digital intelligence as the means, synergization as the goal”. During the Reporting Period, the Group provided nearly 450 alliance clients with multi-scenario solutions tailored to different clinical needs, including AI+ digital intelligence solutions for medical institution alliances, comprehensive collaborations with medical laboratories, solutions for regional/pathology centers and precision medicine center, and specialty-based solutions for alliance development, among other multi-model collaboration services. By leveraging Yunkang’s strengths, the Group assisted healthcare institutions at all levels in enhancing service capabilities and expanding service coverage, established a hierarchical and coordinated healthcare service system, and promoted the development of regional hierarchical diagnosis and treatment services.During the Reporting Period, despite increasingly fierce market competition, the Group maintained solid growth in the joint construction business through continuous deep collaboration with leading hospitals and municipal and county-level hospitals, further consolidating its competitive advantage.“One vertical” ——Joint innovation platform for diagnostic testing serves as strong driver for R&DThe Group has always focused on “clinical needs”, continuously strengthening hospital-enterprise collaboration and pioneering the establishment of a joint innovation platform for diagnostic testing, driving business expansion and product competitiveness. During the Reporting Period, the Group forged joint diagnostic innovation partnerships with dozens of top-tier medical institutions nationwide, delivering a portfolio of testing products addressing multiple infectious syndromes, including respiratory tract infections, central nervous system infections, urinary tract infections, gynecological infections, and tuberculosis, as well as genetic testing products for personalized medication. Collectively, these innovative products have served nearly 300 clients across the country, and achieved sustained growth in testing revenue.During the Reporting Period, Yunkang and Guangdong Provincial People’s Hospital successively launched a series of new panel products covering respiratory tract infections, central nervous system infections, and invasive fungal infections, successfully creating a standardized incubation model for domestic hospital-enterprise research innovation and translation, as well as a “1+N” medical inspection collaboration network. Moreover, throughout the process of scientific and technological innovation, both parties have gained rich clinical experience. With the active involvement and sustained efforts of dozens of domestic diagnostic experts and scholars, they formulated the Expert Consensus on the Application of tNGS for Clinical Standardization, which was published during the Reporting Period in Chinese Journal of Laboratory Medicine, a leading journal in China’s diagnostic field. During the Reporting Period, Yunkang also maintained close collaboration with the First Affiliated Hospital of Guangzhou Medical University, one of China’s top-tier hospitals, and successfully developed a urinary tNGS product, advancing the clinical practice of precision diagnosis and treatment for urinary tract infections. Simultaneously, Yunkang partnered with the First Affiliated Hospital of Jinan University to establish a “university-hospital-enterprise joint innovation platform” and incubated and operated the “innovation project of psychiatric drug genetic testing”, which has successfully yielded genetic testing products for antidepressants, anti-anxiety drugs, and sedative-hypnotics.AI empowers multi-modal solutions for medical institution alliances, improving quality and efficiency to deepen client services During the Reporting Period, Yunkang fully employed DeepSeek and achieved digital deployment across its platforms. Centered on the core concepts of “AI+” and “precision diagnostics”, Yunkang extensively applied artificial intelligence technology across the multi-technology platforms of its medical laboratories. Taking the in-depth integration of AI technology with Yunkang pathology diagnosis platform as an example, the per-slide efficiency of AI-empowered diagnostic was continuously optimized, achieving simultaneous improvements in intelligence, efficiency, and quality. Moreover, through the deployment of intelligent applications, Yunkang realized smart online customer services and the efficient review of results and reports, which fully streamlined diagnostic service processes and improved experience and satisfaction of its client services. In the process of jointly developing new technologies and products through hospital-enterprise R&D, Yunkang’s AI technology empowered product innovation and R&D across multiple aspects, including bioinformatics analysis, report interpretation, disease risk assessment, and development and translation of novel products, by leveraging the powerful data analysis, modeling, and predictive capabilities of large-scale AI models. This has accelerated the clinical implementation.Notably, Yunkang unveiled its medical AI model “ZhiYun” developed in collaboration with Runda Medical and Huawei, spanning the entire clinical workflow from pre-diagnosis to diagnosis and post-diagnosis. It will provide more efficient and convenient support and experience across all stages of clinical medical services. Meanwhile, Yunkang signed a strategic cooperation agreement with Runda Medical to strengthen in-depth collaboration across the industrial ecosystems in “AI + IVD + healthcare services”, jointly promoting the development and application of large-scale AI models in the medical field, and providing clients with digital-intelligence healthcare solutions. In the future, “ZhiYun”, the medical AI model, will be piloted in Yunkang’s healthcare partners and gradually rolled out nationwide, to improve quality and efficiency of medical institution alliance operations.Future prospects2025 marks the final lap for implementing the 14th Five-Year Plan. China has accelerated the capacity expansion of premium healthcare resources and their extension to lower-tier markets, resulting in a more balanced regional distribution. The country has also expedited the development of medical institution alliances and driven their upgrade from “framework building” to “high-quality operation”. Clinical treatment is also shifting from “broad-spectrum therapies” to “precision medicine”, with the growth potential of the industry continuing to be realized. At the same time, AI technology has continued to empower hierarchical diagnosis and treatment services, and the industry is embracing new growth opportunities. Looking ahead, Yunkang will continue to keep pace with industry development trends and align with national policies, further strengthening the value of empowering clinical practices, and persistently exploring the “product innovation + business innovation” dual-pronged model to accelerate business development, deeply empower medical testing services, and benefit more residents.Yunkang Group Limited (Stock Code: 2325)Yunkang Group is a leading medical operation service provider in China, which started to provide standardized medical diagnostic services to medical institutions at all levels as early as 2008. Leveraging its own professional diagnostic capabilities and the nationwide service network of integrated healthcare systems, Yunkang has gradually grown to become a medical operation service platform. Meanwhile, Yunkang is a medical operation service provider in China offering a full suite of diagnostic testing services which are diagnostic outsourcing services and diagnostic testing services for medical institution alliances. Yunkang provides diagnostic services through on-site diagnostic centers to collaborative hospitals in the integrated healthcare systems in China and assists them in improving their clinical diagnosis capabilities through co-developing diagnostic centers. As of today, Yunkang has successfully provided professional services to nearly 450 on-site diagnostic centers. As of June 30, 2025, the hospitals we collaborated with were located across 31 provinces and municipalities in China. Copyright 2025 ACN Newswire via SeaPRwire.com.

SINGAPORE, Aug 27, 2025 - (ACN Newswire via SeaPRwire.com) - TechInnovation® 2025, Singapore’s preeminent platform for innovation and business transformation, returns for its 13th edition from 29–31 October 2025 at Sands Expo & Convention Centre, Level 3 Heliconia and Hibiscus Ballroom, Singapore. Organised by IPI Singapore, the three-day event will bring together over 40 expert speakers, more than 100 breakthrough technologies and curated programmes designed to accelerate real-world innovation and cross-border collaboration.Building on last year’s momentum, which brought together more than 100 exhibitors from 8 countries, attracted attendees from 42 markets, and resulted in over 30 projects supported by IPI Singapore after the event, TechInnovation 2025 will once again convene innovators, startups, corporates, and government agencies across Asia to showcase emerging technology solutions and forge strategic partnerships. In 2024, notably, 46 percent of visitors were senior management decision-makers, underscoring the event’s position as a high-value marketplace for business and technology leaders.The event focuses on sectors including smart buildings, urban solutions, engineering, digital health, sustainability, advanced manufacturing and AI, ensuring businesses can find solutions tailored to their growth ambitions while engaging directly with innovation leaders, potential collaborators and funding partners. Anchored on the theme Discover, Connect and Collaborate, TechInnovation 2025 offers exhibitors and visitors a platform to showcase ready-to-market technologies, connect with potential partners across borders, and co-create solutions to address real-world challenges faced by businesses.Innovation in Action: Interactive BoothsDebuting this year, TechInnovation 2025 will feature experiential technology showcases, giving select exhibitors the chance to showcase their ready-to-market technologies in a hands-on, interactive format. These interactive spaces are designed to spark conversations, encourage engagements and foster meaningful connections across the show floor. For SMEs, the booths offer a unique opportunity to showcase innovations, build credibility and connect directly with potential partners and customers. The launch responds to strong demand for immersive, real-world demonstrations that make technology tangible and memorable.Call for ExhibitorsTechInnovation 2025 invites technology providers, research institutions, startups and solution developers to participate as exhibitors. Exhibitors will benefit from exposure to thousands of decision-makers and industry leaders, targeted business matching opportunities and media visibility through IPI Singapore’s pre-event publicity and digital campaigns.“TechInnovation brings together enterprises and partners to explore new ideas,” said Michael Goh, Chief Operating Officer of IPI Singapore. “We look forward to welcoming exhibitors whose innovations can support practical business applications and contribute to a more sustainable and competitive future.”About TechInnovation 2025Returning for its 13th edition, TechInnovation 2025 is the flagship event of IPI Singapore, connecting technology seekers and providers across Asia. The event serves as a dynamic marketplace for co-innovation and tech adoption, drawing participation from startups, SMEs, corporates, universities and government agencies.This year’s theme, “Discover, Connect, Collaborate” underscores TechInnovation’s mission to drive growth through discovery, global connection and collaboration. The event will feature over 40 speakers, more than 100 technologies and 3 days of programming designed to scale real-world business innovation. TechInnovation is organised by IPI Singapore, a subsidiary of Enterprise Singapore and catalyst of Singapore’s open innovation ecosystem.TechInnovation® is a registered trademark of IPI Singapore.Learn more at www.techinnovation.com.sg.About IPI SingaporeIPI Singapore is an innovation catalyst that creates opportunities for enterprises to grow beyond boundaries. As a subsidiary of Enterprise Singapore, IPI Singapore accelerates the innovation process of enterprises through access to its global innovation ecosystem and advisory services.With a strong belief that innovation is key to enterprise growth, IPI Singapore provides enterprises with access to innovative ideas and technologies. IPI Singapore also facilitates and supports enterprises' innovation processes, including commercialisation and go-to-market strategies.Learn more at https://www.ipi-singapore.org/Media Contact:Sheree TanManager, Marketing & Communications, PartnershipsIPI Singapore ipi_comms@ipi-singapore.orgTheodore WoonDirectorPINPOINT PR Pte. Ltd.theodore@pinpointpr.global Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 28, 2025 - (ACN Newswire via SeaPRwire.com) - On August 27, CALB Group Co., Ltd. ("CALB" or "the Company," stock code: 3931.HK) announced its unaudited condensed consolidated interim results for the six months ended 30 June 2025 (the "Reporting Period"). During the Reporting Period, the Company delivered outstanding operational performance with revenue of RMB16,418.88 million, representing an increase of 31.7% compared to the same period last year, and realized a profit of RMB752.99 million, representing a year-on-year increase of 80.4%. In the first half of 2025, the Company showed strong profitability and resilience during the accelerated trend of transformation of global renewable energy development.According to SNE Research, the Company’s installed capacity of globally EV batteries in the first half of 2025 increased 22.7%, ranking third domestically and fourth globally, with the monthly installed capacity reaching 4.7GWh. The Company was particularly outstanding in the domestic passenger vehicle market with the market share hitting new highs in June and July, reaching 7.4% and 8.25%, respectively. In the energy storage sector, the Company's growth was even more rapid. According to InfoLink, the Company’s shipment in the first half of the year ranked fourth globally, achieving milestone development in the energy storage sector.Centered on continuous technological breakthroughs and with the launch of multiple major products, in the first half of 2025, the Company maintained its leadership in cutting-edge battery technology with the “UP” battery. At the same time, the Company’s 400Wh/kg solid-liquid hybrid battery is poised for mass production and commercial deployment, while significant progress has been made in the all-solid-state battery—including breakthroughs in R&D and the commissioning of a dedicated production line. CALB’s high-power lithium iron phosphate R46 large cylindrical battery is the first in the industry to achieve mass production and has successfully achieved mass production for the latest PHEV models from Geely and Dongfeng. At the same time, the Company’s next-generation lithium manganese LFP battery product achieves an energy density exceeding 210Wh/kg and will also go into mass production. With improved performance, the product can attain 10%- 80% charging within 15 minutes.In the passenger vehicle market, leveraging exceptional product capabilities, the Company achieved full entry into the world’s top three automakers, namely Volkswagen, Hyundai and Toyota. In the first half of 2025, its 800V 5C batteries achieved a monthly sales volume of over 20,000 packs, which will support models for XPeng, Ledao, Leapmotor, Audi, BAIC, and others, and the 800V 5C high-voltage NCM battery exclusively supports popular models such as XPeng’s new P7 with ultra-long range, helping XPeng’s new P7 create a new world record of driving 3,971km in 24 hours.In the commercial vehicle market, CALB has established a comprehensive product matrix architecture for “ZHIYUAN” batteries, covering all scenarios, all applications, and all capabilities. In the first half of year, the Company’s domestic commercial vehicle installed capacity has increased by 310% year-on-year. CALB is the first in the industry to launch a million-kilometer customized products for light trucks, significantly improving the quality assurance of battery systems and effectively enhancing product competitiveness in the market. Leveraging the outstanding recognition from the light truck field, the Company has established in-depth collaborations with customers such as Chery, Geely, Ruichi, Foton, Dongfeng, Changan, and King Long. In the heavy truck field, the Company has deeply cultivated the market through the scenario-based power consumption design and has achieved full-spectrum collaboration by partnering with customers such as Sinotruk, XCMG, SANY, Shaanxi Automobile, Jiefang, Dongfeng, Lingong, and Liugong.The Company has made significant breakthroughs in the international market, and its energy storage business achieved rapid growth in the first half of year. The 314Ah second-generation long-cycle energy storage cell can achieve an ultra-long service life of 15,000 cycles and high energy efficiency of over 96%, while achieving zero degradation in the first 1,000 cycles, earning high recognition from customers for both the product and delivery capabilities. In terms of the overseas market, the Company has successfully partnered with the largest power plant projects in Latin America and South Africa, entering the supplier lists of several leading developers and power grid companies. Meanwhile, the Company’s next-generation “ZHIJIU” of 588Ah and 600Ah+ large energy storage cells will scheduled for mass production within the year.In addition, the Company is the first in the industry to pass the eVTOL power battery manufacturing compliance review and supports the development of China’s low-altitude economy market by actively exploring emerging markets. At present, the R46 cylindrical battery cell with an energy density of 310Wh/kg is now in mass production for leading eVTOL customers in the industry. At the same time, CALB signed a deepened strategic cooperation agreement with GOVY, under which the two parties will carry out in-depth collaboration in the eVTOL sector and jointly promote the development of standardized eVTOL energy products.Overall, in the first half of the year, CALB focused on the strategy of consolidating its leadership in products and technologies, while accelerating the globalization of its production capacity layout. At present, its battery Pack plant in Thailand has been put into operation, while construction of the Portugal base officially commenced in the first quarter of 2025. Looking ahead, with the further improvement of industrial chain system, the Company is expected to leverage its cross-domain, cross-scenario dynamic storage product matrix to achieve deep synergy in its dynamic storage business, creating cutting-edge product capabilities across all scenarios. At the same time, the Company will continuously explore emerging markets such as rail transit, mining, low-altitude flight, and humanoid robots by offering high-safety, high-reliability, and high-performance product solutions. Furthermore, CALB will continue to advance the implementation of its “energy+” strategy, further consolidating its leading position in the global new energy industry.About CALBCALB is a new energy enterprise specializing in the research, production, sales, and market application development of lithium batteries, battery management systems, and related integrated products and lithium battery materials. As Battery Expert, we aim to build a comprehensive energy operation system, to provide complete product solutions and full life-cycle management for the new energy application market, represented by power and energy storage.Currently, CALB has completed an all-round layout in domestic by setting up industrial bases in Changzhou, Xiamen, Wuhan, Chengdu, Hefei, Jiangmen and Meishan. Meanwhile, CALB has set up bases in Europe and ASEAN, vigorously expanding the layout all over the world to become a global leading enterprise with large-scale intelligent manufacturing capabilities. Copyright 2025 ACN Newswire via SeaPRwire.com.